**NIH-CAP 2005-06 Participating Companies**

  ----------------------------------- -----------------------------------
  **21st Century Medicine, Inc.**\    Dean Barry\
  Rancho Cucamonga, CA                Tel: 909-466-8633\
                                      Email: jdbarry@21CM.com

  21st Century Medicine, Inc. has     
  developed novel technologies for    
  cryopreservation and long-term      
  storage of biological tissue        
  slices. Tissue slices are used      
  pervasively during pharmaceutical   
  drug discovery and development,     
  however their use is problematic.   
  Because these tissues can not       
  currently be effectively stored,    
  extensive on-site live animal       
  preparations are required. 21st     
  Century Medicine is currently       
  validating cryopreserved neural,    
  kidney, liver, and intestinal       
  tissue for ADME/Tox testing         
  applications. \                     
  Ready-to-use tissue slices          
  configured for specific testing     
  requirements will significantly     
  increase throughput, reduce on-site 
  testing costs, reduce variation,    
  and further the potential for       
  analytical standardization.         
  Preservation systems for clinical   
  applications are also under         
  development.                        
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **ABIOMED, Inc.**\                  Robert Stewart\
  Danvers, MA                         Tel: 847-491-3280\
                                      Email: rstewart@abiomed.com

  ABIOMED, Inc. is a leading          
  developer, manufacturer and         
  marketer of medical products        
  designed to assist or replace the   
  pumping function of the failing     
  heart. ABIOMED currently            
  manufactures and sells the AB5000™  
  Circulatory Support System and the  
  BVS® 5000 Biventricular Support     
  System for the temporary support of 
  all patients with failing but       
  potentially recoverable hearts.  In 
  Europe, ABIOMED offers the Impella® 
  Recover™ minimally invasive         
  cardiovascular support systems      
  under CE Mark approval.  The        
  Company's AbioCor® Implantable      
  Replacement Heart is the subject of 
  an initial clinical trial being     
  conducted under an Investigational  
  Device Exemption from the United    
  States Food and Drug                
  Administration.                     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Acme Express, Inc.**\             Don Scipione\
  Cleveland, OH                       Tel: 216-391-7400\
                                      Email: dscipione@acmex.com

  Acme Express, Inc. develops         
  healthcare staff scheduling         
  software that cuts schedule-making  
  costs by 80%, optimizes the         
  schedule, and eliminates paper      
  work. Doctors On Call Schedule      
  (DOCS) Request Module mitigates the 
  "negotiations" between staff and    
  the off-time administrator.         
  Generator Module optimizes a fair   
  and accurate schedule.              
  Consolidation Module standardizes   
  and consolidates the entire         
  enterprise call schedule. DOCS      
  eliminates schedule inequity and    
  frees senior medical staff to focus 
  on healthcare delivery rather than  
  contentious scheduling issues.\     
  Our mission is to dramatically      
  increase the productivity of        
  healthcare schedulers.\             
  Our vision is to be recognized as   
  the pioneer in web-enabled medical  
  staff scheduling worldwide.         
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Adherence Technologies**\         Alan Letzt\
  Dulles, VA                          Tel: 703-674-5408\
                                      Email: ALetzt@adherence.com

  Adherence Technologies has          
  developed AccuNurse™, a             
  voice-activated and hands-free      
  system that is revolutionizing      
  long-term care staff documentation, 
  education, and communication.       
  AccuNurse integrates cutting-edge   
  speech recognition, VoIP and        
  Internet technologies with its own  
  proprietary software that further   
  improves speech recognition         
  accuracy and promotes extreme ease  
  of use. We also develop interfaces  
  between AccuNurse, clinical         
  software, other wireless systems,   
  and the facility's main phone       
  system. We install a turnkey        
  system, train the trainers, and     
  provide outstanding client support  
  for this transformation             
  technology.  AccuNurse benefits     
  include dramatically improving      
  quality of care and risk management 
  while reducing nursing home costs.  
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Advanced Brain Monitoring,        Chris Berka\
  Inc.**\                             Tel: 760-720-0099\
  Carlsbad, CA                        Email: chris@b-alert.com

  Advanced Brain Monitoring, Inc.     
  develops and delivers innovative    
  solutions for sleep apnea           
  diagnosis, memory dysfunction       
  measurement and alertness           
  monitoring.  Advanced Brain         
  Monitoring helps clinicians provide 
  better patient care at lower cost   
  with products that combine          
  laboratory level accuracy with the  
  portability, ease of use and        
  affordability of consumer           
  electronics.  The company has       
  chosen to focus on the highly       
  prevalent, underdiagnosed OSA, but  
  Advanced Brain Monitoring systems   
  are applicable to other sleep and   
  neurological disorders.  Advanced   
  Brain Monitoring systems make       
  possible the widespread use by      
  physicians, dentists,               
  industrial/transportation           
  companies, and consumers.           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Aerophase, Inc.**\                Brian Hansen\
  Longmont, CO                        Tel: 847-491-3287\
                                      Email: Aerophase@hotmail.com

  Aerophase Inc. has developed a new  
  Metered Dose Inhaler (MDI) that     
  uses a better propellant and        
  aerosol valve.  Most MDIs used to   
  treat asthma still use CFC          
  (chlorofluorocarbon) propellants    
  and all CFC MDIs will be removed    
  from the market to comply with      
  international environmental laws to 
  stop all CFC production.  The new   
  HFA (hydrofluoroalkane) propellant  
  MDIs cost 3-5 times the CFC         
  propellant MDIs. The Aerophase MDI  
  is superior to CFC and HFA MDIs     
  with better dose control, higher    
  drug delivery efficiency, less than 
  1% of the current propellant cost   
  and less than 0.1 % of the          
  environmental impact.               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Agave BioSystems, Inc.**\         Noe Salazar\
  Austin, TX                          Tel: 512-671-1369\
                                      Email: nsalazar@agavebio.com

  Agave BioSystems has broad          
  capabilities in molecular and       
  microbiology as well as             
  microfabricated and nanoscale       
  systems.  The company's             
  sophisticated laboratories are      
  complemented with access to a broad 
  range of research and development   
  tools and facilities at Cornell     
  University.  Recently we have made  
  important developments in flow      
  cytometry that will lead to two     
  product lines: A suite of novel     
  assays are currently being          
  developed that utilize microspheres 
  and quantum dots.  The advantages   
  of these assays are both improved   
  sensitivity and multiplexing        
  capabilities.   Additionally, a     
  simple yet flexible                 
  microscope-mountable flow cytometry 
  instrument has been developed.      
  This instrument provides a low-cost 
  alternative to conventional flow    
  cytometers and enables new          
  experimentation.                    
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Alan Penn & Associates, Inc.**\   Alan Penn\
  Rockville, MD                       Tel: 847-491-3281\
                                      Email: apenn@alanpenn.com

  Alan Penn & Associates, Inc.        
  develops and commercializes         
  cutting-edge diagnostic image tools 
  that enable clinicians to improve   
  outcomes by detecting cancers       
  earlier and more accurately.  Our   
  initial product, CADimas™, is the   
  first FDA-cleared                   
  computer-aided-detection (CAD)      
  system for breast MRI that helps    
  radiologists screen for and         
  diagnose breast cancer using both   
  lesion shape (morphology) and       
  timing of contrast uptake           
  (kinetics).  R&D has been conducted 
  in collaboration with leading       
  researchers and clinicians at eight 
  major institutions and funded  with 
  \$3.0M in SBIR grants from National 
  Cancer Institute.\                  
  CADimas™ is currently in beta       
  testing.  IP is protected by        
  patents and trade secrets.          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Ambergen Inc.**\                  Richard DelMastro\
  Waltham, MA                         Tel: 847-491-3276\
                                      Email: rdm@ambergen.com

  AmberGen Inc is a molecular         
  diagnostics company focusing on the 
  development of innovative           
  high-value diagnostics for complex  
  diseases.  Our research is based on 
  the relationship of disease         
  phenotype with changes in regional  
  and global methylation that occur   
  at the DNA level.  We have          
  exploited this phenomenon and       
  developed assays for the early      
  diagnosis of lung cancer and to     
  improve the categorization and      
  treatment of asthma.  We have       
  identified novel Asthma DNA         
  methylation biomarkers (AsDMBs) and 
  applied them within a non-invasive, 
  cost effective and easy to use      
  diagnostic format.  The patented    
  prototype diagnostic assay is being 
  validated in a clinical study.      
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **AnaBus**\                         Richard Waterman\
  Jenkintown, PA                      Tel: 215-576-8447\
                                      Email: richard_waterman@anabus.com

  AnaBus synthesizes technological    
  and analytic advances to create     
  efficient and original solutions in 
  the areas of marketing technology,  
  software development and business   
  analytics.  Driven by innovation,   
  we apply technology to perform      
  complicated analytics with greater  
  clarity, disseminate information    
  more widely, and solve problems     
  more cost-effectively for our       
  clients.\                           
  Recent projects:\                   
  -created online surveys for market  
  research projects, performing the   
  development, hosting, recruiting,   
  and statistical analysis in-house.\ 
  -developed an online analytics      
  software platform implementing the  
  propensity scores methodology\      
  -developed automated ATM survey     
  respondent compensation system -ran 
  a national sample, large scale data 
  collection and business analytics   
  project.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **APD Life Sciences**\              Roy Hammerstedt\
  State College, PA                   Tel: 814-234-4835\
                                      Email: hammer@apdls.com

  ADP Life Sciences, Inc. developed a 
  disposable detector for assessing   
  conditions within a variety of      
  sealed containers.  We offer this   
  patent-protected, non-invasive,     
  low-cost detector under sublicense  
  agreement for biomanufacturing      
  applications.  Based upon           
  fluorescent bioindicators, this     
  detector allows for immediate       
  assessment of internal pH, oxygen   
  tension and microbial               
  contamination, and is useful for    
  (a) conformance with developing     
  regulatory requirements for PAT     
  protocols; (b) adjustment of        
  processes for optimum product       
  production; and (c) early detection 
  of undesired organisms.  Given our  
  exceptionally broad experience in   
  many applications, we can work with 
  the licensee to validate and        
  optimize prototypes and protocols.  
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **ApoLife, Inc.**\                  Nalini Motwani\
  Detroit, MI                         Tel: 313-446-2625\
                                      Email: nmotwani@apolife.com

  ApoLife has developed platform      
  expression technologies for the     
  rapid and cost-effective screening  
  and production of recombinant       
  proteins and fully functional human 
  antibodies. The market for          
  therapeutic antibodies is expected  
  to grow to \$30 billion by 2010.    
  ApoLife's yeast system has          
  applications in (I) acceleration of 
  antibody screening and discovery    
  from either hybridoma subclones or  
  phage display libraries, (II)       
  cost-effective production of        
  recombinant proteins and            
  antibodies.\                        
  \                                   
  ApoLife's process requires 1/3 the  
  time for production, thus lowering  
  the cost of capital investment, and 
  has the potential of lowering the   
  cost of final products by up to     
  50%. The company employs Bakers     
  yeast, S. cerevisiae, which has     
  been used for manufacturing of      
  several FDA approved therapeutic    
  products thus providing regulatory  
  competitive advantages over other   
  alternate expression systems. By    
  applying ApoLife's proprietary      
  "Twin Cassette" expression system,  
  biopharma and biotechnology         
  companies can accelerate the        
  process of bringing the new         
  therapies to market and help reduce 
  the healthcare costs.               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Artann Laboratories**\            Noune Sarvazyan\
  Trenton, NJ                         Tel: 512-996-8565\
                                      Email: nsarvaz@artannlabs.com

  Artann Laboratories, Inc. (Artann)  
  is an innovative research company   
  developing a wide range of novel    
  biomedical technologies and         
  products. Patented inventions of    
  Artann include a variety of imaging 
  modalities: mechanical imaging, new 
  approaches to ultrasonic and        
  magnetic resonance elasticity       
  imaging, and shear wave elasticity  
  imaging. Artann also introduced     
  several new medical diagnostic      
  devices, including skin elasticity  
  analyzer, muscle water content      
  tester, colonoscopy force monitor,  
  and a portfolio of scanning bone    
  ultrasonometers.  A new area of     
  Artann research is biomedical and   
  industrial applications of the time 
  reversal acoustics.                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Atom Sciences, Inc.**\            Tom Whitaker\
  Oak Ridge, TN                       Tel: 865-483-1113\
                                      Email: whitaker@atom-sci.com

  Atom Sciences, Inc. (ASI) was       
  founded in 1980. Its original       
  charter was to commercialize a      
  laser-based analytical technology   
  called resonance ionization         
  spectroscopy (RIS) that was         
  developed at Oak Ridge National     
  Laboratory. The company operated    
  for several years as an RIS         
  analytical instrumentation and      
  service company. From this highly   
  specialized market, the company     
  diversified into the designing and  
  installing custom Time-of-Flight    
  (TOF) mass spectrometers. Based on  
  its work in TOF analysis of DNA     
  microarrays, the Company has        
  recently begun developing new       
  technologies related to improving   
  the way genetic information is      
  acquired.                           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Azevan Pharmaceuticals, Inc.**\   Neal Simon\
  Bethlehem, PA                       Tel: 610-419-1057\
                                      Email: ngsimon@azevan.com

  Azevan Pharmaceuticals is a drug    
  discovery and development company   
  producing novel  therapeutics for   
  disorders of stress, mood, and      
  behavior.  The first series of      
  clinical candidates selectively     
  block the effects of arginine       
  vasopressin (AVP), a naturally      
  occurring chemical signal in the    
  body involved in the                
  pathophysiology of conditions that  
  include stress-related affective    
  illness, impulsivity/inappropriate  
  aggression, and menstrual-related   
  disorders.  The chemistry platform  
  can be manipulated to target other  
  G-protein coupled receptors,        
  including high value targets such   
  as the cannabinoid-1 receptor for   
  addiction and obesity.  The         
  receptors targeted by Azevan are    
  also implicated in certain cancers  
  and cardiovascular disease.         
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **BCR Diagnostics**\                Boris Rotman\
  Jamestown, RI                       Tel: 401-849-9957\
                                      Email: bcrbiotech@surfbest.net

  BCR Diagnostics has developed a     
  unique biosensor (termed            
  \"80K-biochip\") based on using     
  engineered spores as fluorogenic    
  nanodetectors. The disposable       
  80K-biochip provides an optimal     
  combination of speed, specificity,  
  sensitivity, and cost effectiveness 
  that is currently unmatched by any  
  other device.\                      
  An advanced application of the      
  80K-biochip is for detecting        
  contaminating bacteria in platelets 
  intended for transfusion.  Other    
  applications include sterility      
  assurance, detection of weaponized  
  biological particles, and           
  environmental monitoring.\          
  A prototypic biosensor has the      
  following specifications:\          
   1. Sensitivity to individual       
  biological particles\               
   2. Testing time of about 15        
  minutes\                            
   3. Cost-effective testing based on 
  disposable biochips\                
   4. Cost-effective instrumentation  
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **BioAssessments, LLC**\            Christopher Hyde\
  Elkton, MD                          Tel: 410-398-1993\
                                      Email: chyde@bioassessments.com

  BioAssessments is developing a      
  promising biological marker into a  
  useful assessment technique.  The   
  initial clinical applications       
  include assessing such diverse      
  medical concerns as attention       
  problems and hypertension.  The     
  value of our product lies in: a)    
  reducing trial-and-error in         
  selecting medications; b) more      
  efficient titration of medications; 
  and c) identifying individuals who  
  might respond adversely to          
  medications.  Our technology could  
  also be used as an alertness        
  monitor for operators performing    
  mission-critical tasks in military  
  and industrial operations.          
  BioAssessments currently builds     
  custom monitoring systems and       
  provides extensive analytical       
  services for researchers at major   
  universities and hospitals to       
  measure this biological marker.     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **BioDetection Instruments**\       Gregory Magness\
  Fayetteville, AR                    Tel: 847-491-3282\
                                      Email:
                                      gmagness@virtual-incubation.com

  \'BioDetection Instruments, LLC was 
  formed in 2002 to commercialize     
  technology for the rapid detection  
  of food pathogens.  Its             
  intellectual property portfolio     
  forms a set of instrumentation      
  characteristics that greatly        
  improve the speed of detection,     
  lower detection limits, and provide 
  quantitative results.  The          
  instrumentation under development   
  is designed for tabletop use in a   
  processing plant environment with   
  minimal operator training           
  requirements.  The company\'s       
  mission is to improve the safety    
  and quality of world food supplies  
  through high-performance            
  biosensors, assay kits, and         
  instruments for the rapid detection 
  of food pathogens and chemical      
  residues.                           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Biomedical Acoustics Research     Richard Sandler\
  Company**\                          Tel: 847-332-2217\
  Evanston, IL                        Email: rhsandler@aol.com

  The Biomedical Acoustics Research   
  Company develops innovative medical 
  diagnostic modalities based on      
  multi-sensor computer-assisted      
  auscultation ("intelligent          
  stethoscopes").  Our technologies   
  simply and instantly provide        
  useful, accurate and low cost       
  information from painless, safe and 
  portable units.  We combine cutting 
  edge digital signal processing,     
  sensor and computer technology with 
  compassionate and informed medical  
  knowledge to help meet important    
  medical market needs.  We're        
  passionate about the tremendous     
  opportunities for implementing      
  these techniques to assist in the   
  diagnosis of many gastrointestinal, 
  pulmonary, musculoskeletal, and     
  cardiovascular conditions.          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Biomedical Development            Phyllis Siegel\
  Corporation**\                      Tel: 210-308-0636\
  San Antonio, TX                     Email: psiegel@biodevcorp.com

  Frio Technologies is a specialty    
  pharmaceutical company dedicated to 
  treating and preventing infections  
  transmitted through the oral        
  cavity.  This is an important       
  emerging market with no market      
  leader.  It is believed by many     
  that the oral cavity is a route to  
  infection leading to stroke, heart  
  disease, diabetes, rheumatoid       
  arthritis, and causing infections   
  in cancer patients, organ           
  transplant recipients, and others.\ 
  Our first product is an oral rinse  
  to treat gingivitis, which is often 
  the first clinical symptom of       
  disease.  We have successfully      
  completed Phase I safety studies    
  and are seeking investment for      
  Phase 2 efficacy and toxicology     
  studies.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Bioscience Development Inc**\     Steven Schutzer\
  New York, NY                        Tel: 973-972-4872\
                                      Email:
                                      grants@biosciencedevelopment.com

  The Company is dedicated to         
  developing diagnostic assays in     
  immunologic and infectious          
  diseases, including Lyme disease,   
  that will be useful to guide        
  therapeutic decisions for humans    
  and animals.                        
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Biostat**\                        Michael Borenstein\
  Englewood, NJ                       Tel: 201-541-5688\
                                      Email:
                                      MichaelB@PowerAndPrecision.com

  Our company develops software for   
  use in research.  The software is   
  used by pharmaceutical companies,   
  universties, and other research     
  organizations.                      
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **BioTechPlex Corporation**\        Donovan Yeates\
  San Diego, CA                       Tel: 858-455-9031\
                                      Email: dyeates@biotechplex.com

  To address the need for new         
  respiratory and cardiac drugs,      
  BioTechPlex/Ceraltics provides cell 
  based HTS screening services and    
  target validation. Through the      
  simultaneous measurements of        
  multiple fluorophores, MAPR         
  provides dynamic fingerprints of    
  the interaction of the "drug" with  
  the cellular target site.  It is    
  1000 times faster than competitive  
  systems, yet has a higher           
  sensitivity and specificity.  Drug  
  discovery is further enhanced       
  through screening of "pathogenic"   
  engineered cell lines for asthma    
  and COPD. Target sites are          
  validated with cell culture-based   
  systems for ciliary activity, water 
  transport, cardiac myocyte beat     
  rate and QT interval.  We predict   
  profitability in the 3^rd^ year.    
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Calibrant Biosystems**\           Don DeVoe\
  Gaithersburg, MD                    Tel: 301-977-7900\
                                      Email: don.devoe@calibrant.com

  Calibrant Biosystems, Inc.          
  discovers, develops, and            
  commercializes protein biomarkers   
  for the diagnosis and treatment of  
  human disease. Calibrant's targeted 
  approach to biomarker discovery     
  provides competitive advantage      
  through proprietary proteomics      
  technologies which are uniquely     
  compatible with limited clinical    
  tissue samples. The company's       
  strategy is based on developing a   
  robust biomarker patent portfolio   
  through targeted collaborations     
  with leading clinical researchers,  
  and biomarker out-licensing to      
  established pharmaceutical and      
  diagnostics companies.              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Callida Genomics, Inc.**\         Ana Drmanac\
  Sunnyvale, CA                       Tel: 408-838-9539\
                                      Email: rade@sbhgenomics.com

  Callida Genomics, Inc. develops and 
  sells advanced whole gene and       
  genome resequencing products and    
  services using proprietary          
  ProbeUniverseTM and combinatorial   
  SBH technologies. Universal Array   
  based HyChip® and                   
  SingleMoleculeGenomeChip have broad 
  applications in research, drug      
  development, and diagnostics for    
  personalized medicine. Universal    
  Array based HyChip® enables reads   
  of 6kb long sequences in a simple   
  two-hour bench assay at lower cost. 
  The HyChip® system further enables  
  high re-sequencing throughput with  
  one inexpensive standard array      
  scanner.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **CCC Diagnostics LLC**\            Paul Tso\
  Baltimore, MD                       Tel: 410-633-4885\
                                      Email: paul@cccdiag.com

  CCC Diagnostics LLC (CCCD) is       
  developing a medical diagnostics    
  technology to establish drug        
  response guides for selection of    
  effective chemotherapy. This        
  information aids physicians in      
  determining a personalized          
  treatment regimen effective for     
  individual cancer patients. The     
  service provided by CCCD is to      
  characterize drug response          
  indicators of tumors by             
  quantitatively measuring the        
  appropriate biomarkers in tumor     
  cells/tumor tissues or circulating  
  cancer cells of the patients.  The  
  validated technology is ready for   
  clinical trials. CCCD plans to      
  enter a partnership with hospitals, 
  institutions or companies in        
  clinical trials followed by         
  commercialization of this patented  
  protected technology and service.   
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **ChanTest Inc.**\                  Arthur Brown\
  Cleveland, OH                       Tel: 216-332-1665\
                                      Email: abrown@chantest.com

  ChanTest has offered drug safety    
  testing and discovery services to   
  biopharma since 1998. The company   
  has grown from 2 to 35 employees,   
  has annual revenues of about \$6MM  
  and has always been profitable.     
  ChanTest has a reputation for       
  providing expertise, accuracy and   
  urgency to its customers. The       
  company is especially expert in the 
  area of ion channels. ChanTest      
  services include proprietary high   
  throughput assays of ion channel    
  function and trafficking and        
  expression of surface membrane      
  proteins in general. Other services 
  include automated patch clamp, GLP  
  in vitro assays and a growing       
  library of cell lines expressing    
  important ion channels. A           
  proprietary antiarrhythmic drug was 
  discovered serendipitously. The     
  drug is safe in man and a Phase 2   
  proof of concept clinical trial     
  received support in a pre-IND       
  meeting at FDA.                     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Chemica Technologies, LLC**\      Takuji Tsukamoto\
  Bend, OR                            Tel: 541-385-0355\
                                      Email: taku@chemica.com

  Chemica Technologies, LLC is a      
  research-oriented, biotech company. 
  Our mission is to develop medical   
  and pharmaceutical products and     
  therapies that significantly        
  improve and enhance the health and  
  quality of life for people          
  world-wide.  Chemica is engaged in  
  both private and Federal fund-based 
  research built on our expertise in  
  biochemistry, chemistry, chemical   
  engineering, and microbiology.  The 
  technologies developed through our  
  research efforts are licensed to    
  strategic partners and investors    
  both nationally and                 
  internationally.                    
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Ciencia, Inc.**\                  Salvador Fernandez\
  East Hartford, CT                   Tel: 860-528-9737\
                                      Email: fernandez@ciencia.com

  Ciencia, Inc. has developed         
  advanced plasmonics biodetection    
  technology for real-time,           
  label-free, highly multiplexed      
  bioassays in microliter volumes.    
  This technology comprises an        
  instrument, and disposable          
  microarray chips.  Detection of     
  pathogens and proteins in serum,    
  and assessment of immune cell       
  phenotype and function in bodily    
  fluids have been demonstrated.      
  Applications include biodefense and 
  immune profiling for diagnosis and  
  assessment of autoimmune,           
  infectious and neoplastic           
  diseases.  Ciencia is a privately   
  held corporation that develops      
  optical sensors and analytical      
  instruments for biodefense,         
  clinical diagnostics, research,     
  process analysis, environmental     
  monitoring, food safety and         
  forensic/security applications.     
  The Company is seeking partners to  
  form R&D joint ventures with an     
  option to license the technology.   
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Clever Sys. Inc.**\               Yiqing Liang\
  Reston, VA                          Tel: 703-787-6946\
                                      Email: yqliang@cleversysinc.com

  Clever Sys. Inc. (CSI) develops and 
  delivers software and systems for   
  automated behavior analysis in life 
  science.  CSI's patent-protected,   
  technology solutions of next        
  generation use intelligent digital  
  video techniques to monitor and     
  analyze lab animal behaviors,       
  provide more new critical and       
  reliable data for scientific        
  research in brain disease, drug     
  discovery, genetic phenotyping, and 
  save huge amount of labor. Our      
  current and potential customers     
  include pharmaceutical companies,   
  biotech companies, and medical and  
  biological research institutes.     
  CSI's current focus is on complex   
  lab animal behaviors, though its    
  technologies can be applied in      
  patient diagnosis, monitoring and   
  rehabilitation, homeland security,  
  market survey, athletes performance 
  analysis.                           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **CogniTech Corporation**\          Jerome Soller\
  Salt Lake City, UT                  Tel: 801-322-0101\
                                      Email: soller@cognitech-ut.com

  CogniTech Corporation develops,     
  markets, and sells customized       
  software solutions for data         
  collection, content management,     
  decision support, simulation, and   
  training.  These technologies are   
  applied to a variety of domains,    
  including emergency response,       
  homeland security, risk assessment, 
  healthcare information systems,     
  clinical trials, and scientific     
  research.  CogniTech Corporation    
  has internationally recognized      
  expertise in many domains,          
  including healthcare informatics,   
  occupational and environmental      
  health, computational chemistry,    
  artificial intelligence, sensor     
  simulation, and e-learning          
  technologies.                       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Communication Disorders           Charles Watson\
  Technology, Inc.**\                 Tel: 812-336-1766\
  Bloomington, IN                     Email: watson@comdistec.com

  Communication Disorders Technology, 
  Inc.(CDT), founded in 1989, has the 
  goal of becoming the market leader  
  in the development of               
  computer-based technologies for     
  speech and hearing professionals    
  (speech pathologists, audiologists, 
  and teachers of the deaf), teachers 
  of foreign languages and of persons 
  with developmental disabilities.    
  Since its beginning CDT has         
  developed speech production and     
  perception testing and training     
  systems that combine                
  speech-recognition technology with  
  state-of-the-art computer           
  graphics.  These systems            
  significantly increase clinical     
  effectiveness and efficiency.       
  CDT's internationally recognized    
  team of investigators has expertise 
  in speech and hearing sciences,     
  psychology, mathematics,            
  engineering, linguistics, graphical 
  arts, and computer programming.     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Conversion Energy Enterprises**\  Barbara Soltz\
  Spring Valley, NY                   Tel: 845-425-9170\
                                      Email: barbara@conversionenergy.com

  Conversion Energy Enterprises (CEE) 
  is developing laser assisted tissue 
  welding systems which consist of    
  miniature lasers, surgical          
  handpieces and light activated      
  bioadhesives for repairing wounds,  
  closing surgical incisions, fixing  
  implants and grafts.  These systems 
  will replace sutures and staples    
  for many surgical applications      
  especially where the surgery is     
  complex or when minimally invasive  
  techniques are required.  The       
  benefits of tissue welding include  
  the reduction in tissue trauma and  
  infection, increased closure speed, 
  improved healing response and       
  eliminates detrimental effects of   
  wound leakage.  CEE\'s systems will 
  have widespread use in              
  herniorrhapy, ophthalmic,           
  orthopedic, urinary and             
  gynecological applications.         
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Core Tech Solutions, Inc..**\     Kirti Valia\
  East Windsor, NJ                    Tel: 609-443-1400\
                                      Email: coretech@att.net

  Core Tech Solutions, Inc. is a      
  Research, Development and           
  manufacturing company dedicated to  
  the science of transdermal (TDS),   
  topical and buccal delivery         
  systems.  The company is developing 
  transdermal patches based on        
  proprietary membrane-controlled     
  technology and drug-in-adhesive     
  technology.  Core Tech has          
  developed patches for pain          
  management and hypertension.  The   
  company has applied patents for its 
  transdermal products.  The company  
  is seeking partners for its         
  Fentanyl-TDS and Clonidine-TDS      
  products.  The company's facilities 
  include R&D laboratory in Mount     
  Laurel, NJ and cGMP manufacturing   
  facility in East Windsor, NJ.  The  
  facility is built in compliance     
  with the FDA and DEA requirements.  
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Creative Action LLC**\            Ronni Sterns\
  Akron, OH                           Tel: 330-867-9978\
                                      Email: RSterns@gwis.com

  Creative Action LLC develops and    
  delivers innovative solutions for   
  the Age 55+ Market. Products        
  targeted to the institutional       
  market improve the quality of life  
  for older adults in long term care  
  facilities and adult day care       
  centers, while improving staff      
  effectiveness, efficiency and job   
  satisfaction. Based on proven       
  behavioral interventions,           
  therapeutic solutions increase      
  engagement and social interaction   
  among people with cognitive         
  impairments; other solutions enable 
  older adults and staff who do not   
  share a common language to          
  communicate with each other.        
  Products targeted to community      
  dwelling older adults maintain      
  independence by improving           
  medication adherence and            
  functioning for successful          
  completion of daily activities.     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **customKYnetics, Inc.**\           Eric Hartman\
  Versailles, KY                      Tel: 859-879-3718\
                                      Email: hartman@customKYnetics.com

  customKYnetics, Inc. is developing  
  exercise and motor retraining       
  devices for use by individuals with 
  neuromotor disabilities secondary   
  to spinal cord injury or stroke.    
  Several of customKYnetics'          
  potential product offerings utilize 
  neuromuscular electrical            
  stimulation (NMES) for the purposes 
  of exercising paralyzed muscles and 
  generating exercise movements that  
  load bones and joints of the lower  
  extremities.  customKYnetics is     
  additionally developing derivative  
  devices which utilize biofeedback   
  with or without NMES to assist      
  clients in regaining voluntary      
  control of paralyzed muscles.       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Cyber Access Systems**\           Don Forest\
  Bryn Mawr, PA                       Tel: 610-527-6391\
                                      Email:
                                      donforest@CyberAccessSystems.com

  Cyber Access Systems® (Cyber) has   
  developed a patented, user          
  interface allowing individuals with 
  severe cerebral palsy (CP) or       
  traumatic brain injury (TBI),       
  including those with quadriplegia,  
  to access a computer.  Cyber will   
  produce two products: (a) a         
  microcomputer-based voice output    
  system, called CyberSpeech®,        
  targeted to persons whose speech is 
  impaired due to CP or TBI, and (b)  
  add-on software to the CyberSpeech® 
  system enabling persons with CP or  
  TBI who are unable to access a      
  computer via a keyboard or mouse to 
  use Windows application programs.   
  To meet the mobility needs of the   
  same population, Cyber will license 
  its user interface technology to    
  manufacturers of power wheelchairs, 
  enabling severely disabled users to 
  move independently.                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Cytograft Tissue Engineering**\   Todd McAllister\
  Novato, CA                          Tel: 415-506-0240\
                                      Email: todd@cytograft.com

  CTE produces tissue engineered      
  blood vessels comprised entirely of 
  the patient's own cells.  The       
  Company's Lifeline™ vascular graft  
  is targeted at four                 
  revascularization indications:      
  hemodialysis patients, lower limb   
  amputation candidates, pediatric    
  patients with congenital defects    
  (cardiac) and coronary bypass       
  candidates.  Unlike previous        
  technologies, the Lifeline™ graft   
  does not rely upon synthetic        
  scaffolds or exogenous biomaterials 
  to provide requisite strength.  The 
  vessel is fully endothelialized,    
  and is a living tissue with an      
  inherent capacity to grow/remodel.  
  The Lifeline™ graft is currently in 
  Phase I/II clinical trials and is   
  the first completely biological     
  tissue engineered vascular graft to 
  be used in man.                     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Detroit R&D, Inc.**\              Hyesook Kim\
  Detroit, MI                         Tel: 313-961-1606\
                                      Email: hskim@aol.com

  Detroit R&D develops ELISAs for new 
  drug development and assay kits for 
  toxicity screening of drug          
  candidates.  Cause of 90% of        
  hypertension is not known.  Thus    
  NON-specific hypertension drugs     
  such as beta blocker, calcium       
  channel blocker and ACE inhibitors  
  induces fatigue, dizziness,         
  depression or birth defect.\        
  The Company's patented Hypertension 
  ELISA kit is based on new finding   
  that increased activity of ONE      
  enzyme is responsible for           
  hypertension.  Clinical data        
  obtained with the Hypertension      
  ELISA revealed that hypertensive    
  urine specimens were significantly  
  different (98% confidence) from     
  normal specimens. New generation    
  hypertension drugs can be developed 
  using the Hypertension ELISA.       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **DIApedia**\                       Martin Bradley\
  State College, PA                   Tel: 814-234-0700\
                                      Email: mbradley@diapedia.com

  DIApedia is a State College,        
  Pennsylvania company developing new 
  products for the treatment and      
  prevention of diabetic foot         
  ulcers.  To date, we have received  
  \$4.2M of NIH SBIR funding to       
  support development of three        
  technologies:  1) CAD-CAM footwear  
  for diabetic patients; 2) a 3-D     
  Haptic Lens used to create a        
  digital image of the plantar        
  surface of the patient's foot; and  
  3) a Load Relieving Dressing system 
  for healing diabetic foot ulcers.   
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Discovery Genomics, Inc.**\       John Haaland\
  Minneapolis, MN                     Tel: 847-491-3279\
                                      Email: johnh@discoverygenomics.net

  Discovery Genomics, Inc. (DGI)      
  utilizes a patented, non-viral gene 
  therapy technology, called the      
  Sleeping Beauty Transposon System,  
  to safely and effectively transfer  
  a gene into the chromosome of the   
  cell, allowing for long-term,       
  stable expression of the correct    
  protein. To demonstrate this        
  technology in humans, DGI will      
  sponsor clinical trials at the      
  University of Minnesota Hospital to 
  treat Fanconi Anemia (FA), a rare   
  and fatal blood disease.            
  Validation of DGI's proprietary     
  technology is expected to lead to   
  cures for other genetically based   
  diseases including Hemophilia A &   
  B, and long-lasting treatments for  
  glioblastoma and breast cancer.     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Eagle Vision Pharmaceutical       Phillip Harnish\
  Corp**\                             Tel: 610-363-6928\
  Exton, PA                           Email: mail@eaglevpc.com

  Eagle Vision Pharmaceutical Corp.   
  is a private development stage      
  company with programs building upon 
  special expertise in the field of   
  injectable imaging agents.  Covered 
  by issued and pending patents, the  
  Company's product candidates        
  enhance Magnetic Resonance          
  Imaging\'s (MRI) powerful potential 
  to revolutionize the diagnosis and  
  management of heart disease, liver  
  disease and cancer, replacing the   
  more limited, costly and invasive   
  procedures currently used.          
  SeeMore™ (EVP 1001-1) represents a  
  significant commercial opportunity  
  as the only intracellular heart     
  agent that is not radioactive.      
  Phase II studies in heart patients  
  are ongoing to demonstrate the      
  superior diagnostic features of     
  SeeMore™ enhanced MRI.              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Engineering Arts**\               Peter Wiktor\
  Mercer Island, WA                   Tel: 206-275-4221\
                                      Email: wiktor@engineering-arts.com

  Engineering Arts is a technology    
  development and manufacturing       
  company currently specializing in   
  piezoelectric \`ink-jet\' fluid     
  dispensing technology.  Current     
  products include the ActivePipette  
  piezoelectric microfluidic          
  dispensers, the DE02                
  SignalGenerator to drive the        
  dispensers and a robotic laboratory 
  automation instrument capable of    
  transferring (pipetting)            
  sub-nanoliter fluid samples with    
  micron positioning accuracy.        
  Engineering Arts' dispensers are    
  used commercially to generate gene  
  expression microarrays. In          
  collaboration with the Fred         
  Hutchinson Cancer Research Center,  
  Engineering Arts is developing a    
  cell-based RNA*i* microarray        
  assay.  Engineering Arts is seeking 
  collaborators to develop other      
  applications that could benefit     
  from microfluidic dispensing and    
  laboratory automation technology.   
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **FEO Medical, Inc.**\              Roy Williams\
  Collierville, TN                    Tel: 901-853-2244\
                                      Email: rewillia@midsouth.rr.com

  FEO Medical, Inc., located in West  
  Tennessee, offers our clients a     
  broad range of R&D services         
  including: mechanical, electronic,  
  optical, software, and systems      
  design; prototype construction and  
  manufacturing interface; and        
  intellectual property assistance    
  via our in-house Patent Agent.  We  
  specialize in LabView and are       
  National Instruments' Alliance      
  Members.  We have worked with a     
  broad range of clients and          
  technologies.  Government-sponsored 
  projects include multiaperture      
  vision tracking systems and         
  multi-spectral imaging systems.     
  Products for commercialization      
  include: deep-UV laser delivery and 
  imaging systems; sleep apnea        
  analysis software; visible          
  lightguide illumination systems;    
  and vacuum-based leak detection     
  systems.  University-based projects 
  include carbon-dating analysis      
  systems.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Fermalogic, Inc.**\               Roy Wesley\
  Chicago, IL                         Tel: 312-738-0050\
                                      Email: roy.wesley@fermalogic.com

  Founded in 1991, Fermalogic is a    
  research-driven biotechnology       
  company that develops and           
  implements strain improvement       
  technology for fermentation-based   
  products to lower the cost of drugs 
  and improve the profitability of    
  pharmaceutical manufacturing. The   
  company\'s research focus is in     
  industrial microbiology as it       
  applies to strain and process       
  improvement for the production of   
  antibiotics and other natural       
  products.\                          
  Fermalogic\'s goal is to bring new  
  technology to the pharmaceutical    
  industry to solve real-world        
  problems in drug production. In     
  response to the never-ending        
  challenge to increase fermentation  
  yield, Fermalogic has developed a   
  strain improvement process based on 
  its patent-pending                  
  FermaChannelingSM metabolic         
  engineering technology.             
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **FM Technologies, Inc.**\          Vadim Jabotinski\
  Chantilly, VA                       Tel: 703-818-9400\
                                      Email:
                                      vjabotinski@fm-technologies.com

  FM Technologies (FMT) develops      
  technology and instrumentation in   
  the area of high-energy, plasma     
  physics and materials processing    
  for industrial, medical, defense,   
  and environmental applications. The 
  company's expertise covers particle 
  accelerators, electron guns, ion    
  beam sources, cathodes, particle    
  beam optics, precision measurements 
  and control and power electronics,  
  vacuum systems, microwave heat and  
  radiation treatment of polymers,    
  metals, ceramics, and composite     
  materials.\                         
  Products for commercialization      
  include: High-brightness penning    
  source of continuous ion beams of   
  O-, H-, Ar+ for biological          
  applications, Microwave joining of  
  ceramics to similar and dissimilar  
  materials, and Electron beam        
  process for prevention of vacuum    
  breakdown in high voltage vacuum    
  devices.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Frontier Scientific, Inc.**\      Bert Israelsen\
  Logan, UT                           Tel: 435-753-1901\
                                      Email: bvi@frontiersci.com

  Frontier Scientific, Inc. (FSI) has 
  developed a drug for iron overload  
  treatment.  Hereditary              
  hemochromatosis (HH), also known as 
  iron overload disease or \"genetic  
  iron poisoning\", is the most       
  common genetic disease in the       
  U.S.A. according to the U.S.        
  Centers for Disease Control and     
  Prevention (CDC). 1 in 8 are        
  \"silent carriers\" of the single   
  HH gene mutation and 1 in 100-200   
  have the double mutation, putting   
  them at high risk for developing    
  full blown HH. HH can affect men,   
  women and children at any age.      
  Currently, individuals with iron    
  overload diseases have phlebotomy   
  treatments, or the removal of a     
  full unit of blood from the         
  patient, conducted in a medical     
  setting one to two times a week.    
  Now, with the drug under            
  development by FSI, an oral dosage  
  prior to a meal will inhibit iron   
  uptake, allowing people to lead a   
  normal life style and save          
  thousands of dollars in medical     
  expenses each year.                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **GeneGo Inc.**\                    Sean Ekins\
  St Joseph, MI                       Tel: 269-930-0974\
                                      Email: sean@genego.com

  GeneGo develops tools for the       
  integration and systems level       
  analysis of high-throughput         
  experimental data in human biology  
  and medicinal chemistry. Our        
  flagship product, MetaCore™,        
  assists scientists in drug target   
  selection, validation, and          
  identification of molecular         
  biomarkers. MetaCore™ is an         
  integrated analytical suite with    
  data parsers, visualization tools   
  and flexible network building       
  algorithms. MetaCore works with the 
  proprietary content of MetaBase™    
  our manually curated database of    
  human biology which allows one to   
  network over 90% of the known human 
  proteins via direct interactions.   
  Our second product, MetaDrug™,      
  deals with prediction of human      
  metabolism and toxicity of novel    
  small molecules and compounds.      
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **General BioTechnology, LLC**\     Erik Woods\
  Indianapolis, IN                    Tel: 317-917-3450\
                                      Email: erik@gnrlbiotech.com

  General BioTechnology (GBT) is a    
  cell processing company based on    
  novel technologies including        
  methods and devices specifically    
  related to giving biological cells  
  and tissues shelf life.  The        
  company has made advancements to    
  improve cryopreservation and        
  banking methods for such diverse    
  cell and tissue types as human      
  pancreatic islets of Langerhans,    
  blood platelets, umbilical cord     
  blood, peripheral blood stem cells  
  and spermatozoa.  Presently, GBT    
  also runs a commercial cord blood   
  bank and anonymous donor and        
  autologous sperm bank.  GBT is      
  registered with the FDA as an       
  HCT/Ps facility and is licensed by  
  the State of Indiana as a Clinical  
  Blood Center Program.               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Genex Technologies, Inc.**\       Matthew Durbin\
  Kensington, MD                      Tel: 301-962-6565\
                                      Email: matthew.durbin@genextech.net

  Founded in 1995, Genex Technologies 
  is a world leader in 3D Imaging, 3D 
  facial recognition, and intelligent 
  surveillance.\                      
  Genex's highly accomplished staff   
  of engineers and project managers   
  deliver practical solutions to some 
  of today's most challenging imaging 
  needs. With internal expertise in   
  fields ranging from optics to       
  mechanical design to electronics,   
  Genex's innovative team solves      
  complex problems every day.\        
  Genex offers solutions and design   
  competencies in the following       
  areas:\                             
  High-Speed 3D Capture\              
  3D Editing and Post-Processing\     
  3D Data Manipulation\               
  3D Display The Intelligent\         
  Optical Design\                     
  High-Speed Image Processing\        
  Algorithm Development\              
  Remote, Unmanned Applications\      
  WatchList\                          
  Access Control\                     
  Composite Sketching                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **GLSynthesis Inc.**\               George Wright\
  Worcester, MA                       Tel: 508-754-6700\
                                      Email:
                                      george.wright@glsynthesis.com

  GLSynthesis is a 9-year old,        
  private company that performs       
  laboratory scale (custom) organic   
  synthesis, drug discovery research, 
  and chemical product manufacturing. 
  Customers include major US and      
  international pharmaceutical        
  companies, startup drug discovery   
  and \"virtual\" companies,          
  biotechnology companies, suppliers  
  of fine chemicals, nutriceutical    
  companies, and academic and         
  research institutions. Drug         
  discovery, including in vitro and   
  in vivo pharmacology and            
  pharmacokinetics, is accomplished   
  through corporate contracts and     
  small business (NIH) grants. We     
  have developed the Fluorosome       
  Technique for drug absorption and   
  disposition studies, and are        
  actively marketing it. We develop,  
  market, and sell several specialty  
  chemicals worldwide, produced       
  directly by our affiliate company   
  Shanghai GLSynthesis, Shanghai,     
  China.                              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Goldfinch Diagnostics Inc.**\     Louis Kirchhoff\
  Iowa City, IA                       Tel: 319-335-6786\
                                      Email: louis-kirchhoff@uiowa.edu

  Goldfinch Diagnostics Inc. was      
  founded in 1997 with the goal of    
  developing diagnostic assays for    
  infectious diseases.  To date its   
  activities have been focused on the 
  development of hybrid recombinant   
  antigens useful for the diagnosis   
  of Chagas disease.  The primary     
  support for these activities has    
  been a SBIR grant from the NIH.     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Gwathmey, Inc.**\                 Judith Gwathmey\
  Cambridge, MA                       Tel: 617-491-0022\
                                      Email: jgwathmey@gwathmey.com

  Gwathmey, Inc. the "The Thinking    
  Pre-Clinical Contract Research      
  Organization" ^TM^ provides both    
  GLP and non-GLP studies for in vivo 
  and in vitro drug screening for     
  lead compounds, pharmacokinetic,    
  toxicology, biodistribution studies 
  and efficacy testing in animal      
  models. We work in the Arthritis,   
  Cancer, Cardiovascular, CNS,        
  Infectious Disease, Diabetes and    
  Obesity therapeutic areas. Our      
  world-class scientists and          
  state-of-the-art research           
  facilities are used to conduct      
  proof-of-concept and key            
  experiments for FDA drug approval.  
  We significantly change the         
  risk-reward profile and effectively 
  bridge the difficult gap between    
  chemistry and biology. Our goal is  
  to conduct efficient,               
  physiologically sound studies in    
  order to provide high quality data  
  for quality drug development        
  decision making.                    
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **HemoGenix, Inc**\                 Ivan N. Rich\
  Colorado Springs, CO                Tel: 719-264-6250\
                                      Email: ivannrich@hemogenix.com

  HemoGenix specializes in developing 
  and producing sensitive in vitro    
  luminescence proliferation assays   
  to meet the need in 3 market areas. 
  These include detecting and         
  predicting hemotoxicity during drug 
  discovery and development,          
  multifunctional research assays for 
  basic research and quality control  
  in stem cell transplantation and    
  cord blood storage processing       
  laboratories. The HALOTM Platform,  
  fulfils all 3 arenas as both a      
  contract service and a product line 
  of over 400 assay kit variations.   
  HemoGenix provides these services   
  and kits worldwide. HALOTM and its  
  applications is one of 4            
  luminescence assay products within  
  the HemoGenix intellectual property 
  portfolio.                          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **IA, Inc. / ThreeFold Sensors**\   Judith Erb\
  Ann Arbor, MI                       Tel: 734-995-9338\
                                      Email: jerb@threefoldsensors.com

  ThreeFold Sensors, Inc. (TFS)       
  develops and markets portable       
  biosensor instruments and a variety 
  of sensor cartridges having         
  applications in medical diagnostics 
  and environmental testing.  Our     
  sensors provide, in 3 minutes,      
  results of comparable sensitivity   
  to those obtained by immunoassays   
  requiring 4-24 hours. The           
  technology has been developed       
  through \$7.5 million in SBIR       
  grants and is protected by seven    
  pending patents. Our instrument\'s  
  small size brings reference lab     
  quality tests to field testing and  
  point of care settings.  Our panel  
  of rapid reproductive hormone tests 
  will be introduced to fertility     
  clinics in 2006.  Sensors for       
  assessing which pharmaceuticals     
  will best treat an individual\'s    
  cancer are in development.          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **IBET, Inc.**\                     Eric Plum\
  Columbus, OH                        Tel: 614-487-1379\
                                      Email: eplum@IBETInc.com

  IBET Inc.'s corporate focus is on   
  research and development of         
  instrumentation for the             
  biochemical, biophysical, and       
  biomedical sciences.  The company's 
  expertise and experience in         
  biothermodynamics has inspired      
  development of  proprietary         
  technology for monitoring thermal   
  and thermodynamic properties of     
  macromolecules; specifically,       
  temperature-dependent UV/Vis        
  spectroscopy and ultrasonic         
  velocimetry.  IBET Inc. has         
  developed analytical instruments    
  designed to provide new and unique  
  information about the thermodynamic 
  properties of biologically          
  important macromolecules and        
  biomolecular interactions.  These   
  instruments address a deficiency in 
  high-throughput thermodynamic       
  methods resulting from the          
  explosive growth in knowledge of    
  DNA and protein sequence            
  information.                        
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Ichor Medical Systems, Inc.**\    Robert Bernard\
  San Diego, CA                       Tel: 858-550-2022\
                                      Email: rbernard@ichorms.com

  Ichor Medical Systems has developed 
  a powerful, patented                
  electroporation technology for      
  delivery of DNA drugs.  Although    
  electroporation is a broadly        
  utilized method for DNA drug        
  delivery in various animal models,  
  commercialization of this           
  technology has been hindered by the 
  lack of a reliable and clinically   
  acceptable means for human          
  administration.  Ichor's            
  proprietary TriGrid™ Delivery       
  System integrates several patented  
  electroporation technologies into a 
  simple handheld clinical device     
  that enables safe, efficient and    
  reproducible DNA administration     
  with minimal clinical training.     
  This powerful technology delivers   
  on the promise of DNA drugs and     
  vaccines, addressing the            
  significant unmet medical needs of  
  numerous debilitating and life      
  threatening diseases.               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **INCELL Corporaton, LLC**\         Mary Pat Moyer\
  San Antonio, TX                     Tel: 210-877-0100\
                                      Email: mpmoyer@incell.com

  INCELL has developed innovative and 
  patented platform technologies for  
  non-needle vaccine delivery and     
  intends to make an impact on global 
  health by changing the vaccine      
  delivery paradigm. Its oral and     
  nasal smallpox vaccines will        
  complete Phase I/II clinical trials 
  by Q3 2006 and provide supportive   
  technology information to           
  influenza, HIV and other vaccines   
  in development. INCELL manufactures 
  and sells products to biotechnology 
  and pharmaceutical markets, and     
  provides contract research services 
  relevant to pre-clinical and        
  clinical products for infectious    
  disease, regenerative medicine,     
  stem cells, chem-bio defense, and   
  cancer. INCELL has a strong         
  multi-product pipeline, including a 
  cancer nutraceutical in clinical    
  trials.                             
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **INFOTECH Soft, Inc**\             Mansur Kabuka\
  Miami, FL                           Tel: 305-670-5111\
                                      Email: kabuka@infotechsoft.com

  INFOTECH Soft, Inc. specializes in  
  the application of XML and Web      
  technologies to create              
  next-generation software solutions  
  for health and life sciences        
  research. INFOTECHSoft's ASPECT     
  clinical trial management system    
  combines intelligent electronic     
  form and trial models designed      
  around XML Schema, which contain    
  instructions for sophisticated data 
  verification, automated             
  calculation, and conditional        
  processing. The system can be       
  deployed in single location studies 
  or large, multi-center clinical     
  trials communicating over Internet  
  connections. It increases data      
  accuracy and enables timely         
  protocol compliance monitoring,     
  reducing the overall costs of       
  executing a clinical trial and the  
  total time-to-market of promising   
  drugs or therapies.                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Inframat Corporation**\           Zongtao Zhang\
  Willington, CT                      Tel: 847-491-3277\
                                      Email: zzhang@inframat.com

  Inframat® is a global leader in the 
  development and commercial sale of  
  powder and solution feedstocks for  
  thermal sprayed industrial          
  nanocoatings and currently holds    
  over one dozen nanocoatings patents 
  (U.S. and foreign).  Inframat\'s    
  ceramic nanocoating product,        
  NanoxTM 2613 Thermal Spray          
  Feedstock, which received an R&D100 
  Award in 2001, has been in use on   
  shipboard (propeller shafts) for    
  several years and is currently is   
  \"spec'd\" and blueprinted with the 
  U.S. Navy.  Inframat® has applied   
  similar nanocoatings to medical     
  applications, and has licensed this 
  patented technology to a major      
  orthopedics company.  Inframat®     
  Advanced Materials, a commercial    
  subsidiary, sells nanomaterials     
  throughout the world.               
  ----------------------------------- -----------------------------------

  ----------------------------------- ---------------------------------------------
  **Integrative BioInformatics,       Ann Chasson\
  Inc.**\                             Tel: 650-906-4876\
  Los Altos, CA                       Email:chasson@integrativebioinformatics.com

  Integrative Bioinformatics is a     
  scientific software and consulting  
  services company with expertise in  
  the modeling and analysis of        
  biological systems.  Our software   
  product, ProcessDB, helps molecular 
  cell biologists, physiologists and  
  pharmacologists manage and test     
  their increasingly complex          
  mechanistic hypotheses. ProcessDB   
  does this with a powerful but       
  biologically intuitive graphical    
  user interface that helps           
  biomedical researchers formulate,   
  visualize and test their theories   
  of cellular and physiological       
  function. ProcessDB allows          
  investigators to know what their    
  theories predict for any collection 
  of experimental designs, and it     
  speeds discovery of mechanisms that 
  account for all of the available    
  experimental data. By leveraging    
  database, kinetic modeling, and     
  visualization technologies,         
  ProcessDB supports knowledge        
  management for research             
  organizations working on complex    
  biological problems.                
  ----------------------------------- ---------------------------------------------

  ----------------------------------- -----------------------------------
  **Intrinsic Bioprobes, Inc.**\      Randall Nelson\
  Tempe, AZ                           Tel: 480-804-1778\
                                      Email: rnelson@intrinsicbio.com

  IBI's mission is to improve the     
  diagnosis and treatment of disease  
  through the application of novel    
  proteomics technologies and         
  findings".\                         
  IBI's proprietary technologies are  
  used in the study of diseases for   
  biomarkers discovery/validation and 
  subsequent diagnostic application.  
  Presently, IBI operates in the      
  proteomics instrumentation,         
  services and intellectual property  
  markets, with respective offerings  
  of MASSAY® analytical systems,      
  contract research programs and      
  licensing arrangements.             
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Ionwerks, Inc**\                  Ketti Eipers-Smith\
  Houston, TX                         Tel: 713-522-9880\
                                      Email: kes@ionwerks.com

  Ionwerks, Inc. designs and          
  manufactures a complete line of     
  instrumentation and electronics for 
  Time-of-Flight (TOF) mass           
  spectrometry.  Our patented         
  instrument couples ion-mobility     
  (IM) of MALDI desorbed ions with    
  orthogonal time of flight (oTOF)    
  mass spectrometry to provide        
  analysis of small molecules         
  unidentifiable by MALDI alone, such 
  as drugs of abuse, lipids, and      
  neuropeptides.  Ionwerks'           
  revolutionary technology can        
  simultaneously separate and         
  identify low mass ions while        
  analyzing larger mass ions from     
  intact molecules and biomolecules.  
  In addition to important biological 
  and clinical applications, the      
  generalized techniques and          
  instrumentation are applicable to   
  numerous other fields, including    
  materials analysis and              
  environmental sampling.             
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Kinetic Muscles, Inc.**\          Ed Koeneman\
  Tempe, AZ                           Tel: 480-557-0448\
                                      Email: ekoeneman@kineticmuscles.com

  Kinetic Muscles, Inc. products help 
  people with neurological disease    
  such as stroke to improve the use   
  of their hands, arms and legs.  We  
  make the first and only multi-modal 
  active-motion device for home and   
  clinic based therapy of             
  neuromuscular disability.   Says    
  one user, \"Regaining my grip has   
  changed my outlook on getting my    
  life back.\"  KMI is poised to      
  accelerate from the current         
  convergence of neuroscience         
  advances, a home healthcare trend   
  and its early foothold in the       
  neurotherapy market.  Its products  
  are an important, cost-effective    
  solution that improves the quality  
  of life for millions of people.     
  The accomplishments and experience  
  of its team have demonstrated a     
  path toward success.                
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Kumetrix, Inc**\                  Wilson Smart\
  Union City, CA                      Tel: 510-476-0950\
                                      Email: smart@kumetrix.com

  Kumetrix has developed a unique     
  medical diagnostics technology      
  based on bioMEMS                    
  (Micro-Electro-Mechanical           
  Systems).  A single-use disposable  
  silicon microchip, with integrated  
  hollow microneedle comparable in    
  size to a human hair, punctures the 
  skin, draws a sub-microliter blood  
  sample into the body of the chip,   
  and performs a specific assay       
  without subsequent blood transfer.  
  The chip mates with the actuator of 
  a handheld meter, which             
  automatically performs the puncture 
  under microprocessor control, reads 
  the assay, displays the result, and 
  stores it in memory.  This          
  single-step method renders blood    
  testing painless, rapid, clean, and 
  inexpensive, while requiring no     
  skill from the operator.            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Leo Lens Technology**\            Praful Doshi\
  San Diego, CA                       Tel: 858-335-2873\
                                      Email: prafdoshi@leolens.com

  Leo Lens Technology, Inc. has       
  developed the next generation       
  product for the lucrative \$4       
  Billion contact lens industry.      
  With the Leo Lens technology, exact 
  coloring and iris imaging can now   
  be achieved creating a superior     
  product for the cosmetic and        
  prosthetic segment.  This globally  
  patented and FDA approved           
  technology is ready for             
  manufacturing scale-up. Leo Lens is 
  looking for both strategic and      
  financial partners to fully         
  commercialize this innovative       
  product.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **LIFETECHniques, Inc.**\           Karen West\
  Santa Barbara, CA                   Tel: 561-317-8106\
                                      Email: karen@medsignals.com

  MedSignals™ is a product line of    
  communicating medication devices to 
  aid adherence. The smart pillboxes  
  alert at pill times, time-stamp     
  usage with each lid opening, upload 
  data to servers daily, and post     
  usage times on charts for           
  authorized caregivers. As a data    
  collection tool, MedSignals imports 
  easily to spreadsheets. A handheld  
  MedSignals pillbox showed           
  significantly improved compliance   
  in one NIAID-funded study. Other    
  models in development include a     
  wireless model for chronically ill  
  children with a GPS locator.        
  MedSignals will introduce its first 
  commercial model in August, 2006.   
  It will sell through insurance      
  plans, trade shows, medical supply  
  companies and pharmacies.           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Lohocla Research Corporation**\   Boris Tabakoff\
  Denver, CO                          Tel: 303-724-3668\
                                      Email: boris.tabakoff@uchsc.edu

  Lohocla is a preclinical-stage      
  company focused on the therapy and  
  diagnosis of pain, psychiatric and  
  addictive disorders.  The lead      
  product, DCUK, is a patent          
  protected, novel compound that has  
  demonstrated biological activity in 
  animals for pain, anxiety, and      
  alcohol dependence.  The lead       
  indication is severe chronic pain.  
  The pain management market is over  
  \$32 billion in the USA, and        
  current medications are             
  suboptimal.  To date DCUK has been  
  shown to be safe, and to have       
  significant activity for severe     
  pain.  Lohocla is currently         
  conducting preclinical FDA studies  
  to pursue potential indications for 
  phantom limb pain, cancer pain, and 
  dental pain.                        
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Lucid Inc.**\                     Jay Eastman\
  Rochester, NY                       Tel: 585-239-9800\
                                      Email: jme@lucid-tech.com

  Business Description: Lucid, Inc.   
  is a medical device and information 
  company that has developed,         
  patented, and produced confocal     
  microscopes (trademarked as         
  VivaScopes®) that produce images of 
  living cells for real-time medical  
  imaging and diagnosis in a doctor's 
  office.  VivaScopes®, when coupled  
  with Lucid's patented digital       
  pathology PACS system, allows       
  real-time diagnosis of many         
  malignant diseases - without the    
  need for invasive biopsy.  Lucid    
  intends to launch its products for  
  dermatologic surgery followed by    
  screening of skin cancers.          
  Ultimately the technology can be    
  applied in many other areas of      
  diagnostic and surgical pathology.  
  Lucid's business model derives      
  revenues from device sales and from 
  transaction fees for its digital    
  pathology PACS services. As the     
  installed base of VivaScopes®       
  grows, Lucid will derive the        
  majority of its revenues from       
  transaction fees.                   
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Lynntech, Inc.**\                 Scott McKenzie\
  College Station, TX                 Tel: 979-693-0017\
                                      Email: scott.mckenzie@lynntech.com

  Lynntech is an \"innovation         
  engine\", applying in-depth         
  experience in research, technology  
  development, prototyping, and       
  product commercialization. We       
  perform research and development    
  for a variety of clients (leading   
  corporations, Federal R&D and       
  venture capital) helping them meet  
  their strategic goals under the     
  ever-increasing pressures of faster 
  technology cycles and heightened    
  competition. Our advanced life      
  sciences chemistries and devices    
  business strategy focuses on        
  creation of value for early and     
  prototype stage inventions and      
  intellectual property derived       
  internally and/or in partnership    
  with leading university faculty     
  inventors. Lynntech growth is       
  achieved through partnerships       
  offering cutting-edge technologies  
  for licensing, and through the      
  creation of investment              
  opportunities in new ventures.      
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Maine Molecular Quality Controls, Joan Gordon\
  Inc.**\                             Tel: 207-885-1072\
  Scarborough, ME                     Email: jgordon@mmqci.com

  Maine Molecular Quality Controls,   
  Inc. (MMQCI) provides the           
  biomedical industry with            
  innovative, high-quality control    
  products for molecular diagnostics. 
  MMQCI products fulfill Federal      
  regulations by monitoring the       
  entire molecular laboratory test,   
  including extraction. Products are  
  composed of synthetic nucleic acid  
  constructs stabilized by a unique   
  proprietary matrix. All are         
  uniquely designed to be analyzed as 
  natural biological samples. Unlike  
  biologicals, MMQCI controls contain 
  multiple mutations in single        
  samples. This key feature renders   
  the controls comprehensive and cost 
  efficient, allowing more complete   
  quality assurance. Products are     
  non-infectious, facilitate          
  documentation requirements and      
  provide consistent results to aid   
  the identification of potential     
  system problems.                    
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Maxwell Sensors Inc**\            Winston Ho\
  Santa Fe Springs, CA                Tel: 562-801-2088\
                                      Email: winstonho@maxwellsensors.com

  Maxwell Sensors Inc has developed a 
  proprietary microfluidic bio-disc   
  technology. The microfluidic        
  chemiluminescence (MCL)-bio-disc    
  products offer multiplexed assays,  
  rapid test results, and             
  significantly more sensitivity      
  (100 - 1,000 times) and accuracy    
  than the current Point of Care      
  Testing systems.  The technology    
  provides "low cost",                
  \"miniaturization\",                
  \"integration\", and \"total        
  automation\" for a wide variety of  
  immunoassay and molecular           
  diagnostic applications. Cardiac    
  markers and infectious diseases     
  panel tests are our initial market  
  applications.                       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Microwave Imaging System          David DeLucia\
  Technologies**\                     Tel: 802-649-8109\
  Norwich, VT                         Email: delucia@biosystemdesign.com

  MIST Inc. is an early stage medical 
  device company which has            
  demonstrated an improved system for 
  breast cancer screening and         
  diagnosis. The addressable market   
  is 40 million women in the US       
  (\$4B/yr in screening service from  
  \>\$1B of capital equipment). The   
  worldwide market is four times      
  larger.\                            
  In human clinical testing of \>150  
  patients at the Dartmouth-Hitchcock 
  Medical Center we have demonstrated 
  performance equivalent to an MRI at 
  one tenth the cost. This success    
  reflects over \$6M invested by the  
  National Institute of Health in     
  developing our technology.\         
  Intellectual property is issued and 
  wholly owned.                       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Molecular LogiX, Inc**\           Daniel Monticello\
  The Woodlands, TX                   Tel: 847-491-3284\
                                      Email:
                                      dmonticello@molecularlogix.com

  \'Molecular LogiX is a drug         
  discovery company. The Company is   
  developing a new class of           
  protein-based therapeutics to treat 
  cancer. Our initial focus is on     
  developing Anti-Cancer Ligands      
  (ACL) directed against Receptor     
  Tyrosine Kinases (RTK) implicated   
  in cancer. We have developed a      
  potent new "Pan-HER" ACL that has   
  the potential to be a valuable new  
  weapon in the fight against cancer. 
  This "First in Class" compound      
  reflects an entirely new approach   
  to interfering with the             
  RTK-dependent progression of        
  disease. The Company's business     
  strategy is to develop the drug     
  leads it creates through Phase II   
  clinical trials and then partner    
  them with larger biotechnology and  
  pharmaceutical companies.           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Molecular NeuroImaging**\         Kenneth Marek\
  New Haven, CT                       Tel: 203-401-4300\
                                      Email: kmarek@mnimaging.com

  Molecular NeuroImaging, LLC (MNI)   
  is a neuroimaging services company  
  specializing in the efficient       
  application of scintigraphic        
  biomarkers in drug development and  
  clinical research for               
  neurodegenerative and               
  neuropsychiatric disorders.   MNI   
  provides services across the        
  pre-clinical and clinical spectrum  
  including radioligand development,  
  design and implementation of Phase  
  1 to Phase 4 clinical imaging       
  trials, and customized clinical     
  imaging site coordination and       
  management in multi-site imaging    
  studies. Our strong emphasis is on  
  using investigational radiotracers  
  with quantitative imaging outcome   
  measures as diagnostic tools and/or 
  for assessing disease mechanism or  
  progression.  Our focus is on       
  developing radioligands as tools    
  for human research.                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **MRPath Incorporated**\            Robert Lontz\
  Durham, NC                          Tel: 919-806-0081\*308\
                                      Email: rjlontz@mrpath.com

  MRPath, Inc. specializes in the     
  conduct of high performance         
  magnetic resonance imaging (MRI)    
  protocols for accelerating the      
  discovery of new biopharmaceutical  
  targets and evaluation of their     
  safety, and rodent models of        
  disease and toxicity. Our           
  technology enables the study of     
  effects in the same animal over     
  extended times, and                 
  three-dimensional imagery of        
  in-context bio-structure with       
  exceptional resolution and field of 
  view. Unlike previous technologies, 
  the company's technology enables    
  quantitative morphological          
  measurement. MRPath integrates its  
  MRI with complementary imaging      
  technologies into image-centric     
  study report formats, which are     
  available to customers in a         
  web-enabled document and image      
  management system.                  
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Nanoprobes, Incorporated**\       Richard Powell\
  Yaphank, NY                         Tel: 919-845-6324\
                                      Email: rpowell@nanoprobes.com

  Nanoprobes, Incorporated researches 
  and develops novel technology for   
  the detection and visualization of  
  biological targets using targeted   
  metal nanoparticles and             
  metallographic reactions. The       
  company is developing improved      
  X-ray contrast agents for           
  angiography and vascular imaging    
  which provide enhanced sensitivity, 
  combined with low toxicity and very 
  low viscosity, thus minimizing      
  vascular damage and enabling        
  imaging in organs such as the       
  brain, or in obese patients where   
  current contrast agents are not     
  well tolerated. These reagents are  
  also applicable to the specific     
  imaging of cancer, and              
  high-resolution imaging of smaller  
  blood vessels and features          
  (Micro-CT).                         
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Neuronautics, Inc.**\             Sam Khatami\
  Evanston, IL                        Tel: 847-491-3271\
                                      Email: skhatami@neuronautics.com

  Neuronautics, Inc. ("NNI" or the    
  "Company") was founded in 1997 with 
  the mission to develop diagnostic   
  and therapeutic treatments for the  
  early detection and eventual        
  prevention of Alzheimer's disease   
  (AD) and other related              
  neurodegenerative disorders. These  
  disorders are characterized by the  
  formation of structures called      
  neurofibrillary tangles (NFTs) from 
  molecules of tau protein that       
  associate into insoluble polymers.  
  The Company believes that drugs     
  that can inhibit or prevent NFT     
  formation will prevent the          
  progression of AD or, given early   
  diagnosis, potentially reverse the  
  course of the disease. In           
  collaboration with leading experts  
  and renowned academic institutions, 
  NNI has discovered several potent   
  anti-tangle drug candidates.        
  Eventually, NNI anticipates         
  partnering with major               
  pharmaceutical companies to take    
  these compounds through the         
  clinical testing necessary to       
  support FDA approval.               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **NOCwatch International, Inc.**\   Kathryn Kelly\
  Crystal Bay, NV                     Tel: 775-833-4142\
                                      Email: kek@nocwatch.com

  Our nation's elderly fall about 10  
  million times per year, frequently  
  incurring major disability and      
  significant social and economic     
  costs.  NOCwatch has completed two  
  clinical trials resulting in the    
  first device ever shown to reduce   
  falls and injuries in this          
  high-risk population.  It does so   
  with a small, inobtrusive patch     
  attached like a band-aid to the     
  patient\'s thigh that reliably      
  alerts staff or family that a       
  patient is trying to get up         
  unassisted, without sending false   
  alarms.  The alarm in the room      
  reminds the patient that they are   
  not to get up unassisted (which     
  works particularly well with        
  dementia patients), and can also be 
  connected to a nurse call system to 
  call a nurse or page a relative.    
  The low-cost, Class I-exempt device 
  is worn for up to three weeks       
  before being disposed of with       
  regular waste, and can be worn      
  while bathing and during x-rays,    
  MRIs, etc.  More information can be 
  found at www.nocwatch.com.          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Novarx Corporation**\             Habib Fakhrai\
  San Diego, CA                       Tel: 847-491-3285\
                                      Email: fakhrai@novarx.com

  NovaRx has developed and utilized a 
  technology that has significantly   
  prolonged survival and improved the 
  quality of life in cancer           
  patients.\                          
  NovaRx is a clinical-stage          
  biopharmaceutical company.  It\'s   
  lead product, Lucanix™, is at the   
  end of a Phase II clinical trial    
  for the treatment of non-small cell 
  lung cancer. Results demonstrate    
  median survivals more than twice    
  that of approved drugs with only    
  minor toxicities.   NovaRx is       
  meeting with the FDA in the fourth  
  quarter of 2005 in order to         
  initiate a Phase III clinical trial 
  for Lucanix™ in early 2006.\        
   NovaRx hopes its additional        
  technologies under development will 
  transform cancer into a             
  controllable disease such as        
  diabetes.                           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Optimer Pharmaceuticals, Inc**\   Alex Romero\
  San Diego, CA                       Tel: 858-909-0736\
                                      Email: aromero@optimerpharma.com

  Optimer Pharmaceuticals, Inc., a    
  privately held San Diego-based      
  company, has two late-stage drugs   
  to treat life-threatening bacterial 
  infections under development\       
  and a range of preclinical          
  antibiotics discovered through our  
  powerful carbohydrate drug          
  discovery engine.  Optimer\'s core  
  competence includes the development 
  of innovative drugs for treating    
  diseases that currently have no     
  satisfactory therapy. These include 
  antibiotics for drug-resistant      
  bacterial infections, a cancer      
  vaccine, and \"disease-modifying\"  
  drugs for osteoarthritis.  In the   
  near term Optimer plans to bring in 
  significant revenues through        
  sponsored research, joint ventures, 
  government grants, and license      
  royalties.                          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Panomics, Inc.**\                 Jason Li\
  Redwood City, CA                    Tel: 650-216-9736\
                                      Email: jasonli@panomics.com

  Panomics, Inc., incorporated in     
  California in September 2000, is a  
  biotechnology-based company         
  dedicating to the development of    
  innovative tools for the functional 
  studies of proteins.  Panomics      
  began its official operations on    
  November 2000 and launched its      
  products on July 2001.  Since then, 
  the company has been launching more 
  than one thousand products to the   
  market.  Panomics has established   
  an international distribution       
  network covering all major          
  countries and is establishing its   
  sales network in North America.     
  Panomics was ranked #4 among 100    
  fastest-growing companies in San    
  Francisco Bay area by San Francisco 
  Business Times and #6 among 50      
  fastest-growing private companies   
  in Silicon Valley by San Jose       
  Business Journal in 2004. Panomics  
  has been awarded 7 SBIR/STTR grants 
  of total \$2.5M by the National     
  Institutes of Health (NIH).         
  Panomics has become a profit        
  organization since 2003, Panomics   
  acquired in 2003 FreshGene, a small 
  biotech company engaged in the      
  development of SNP detection        
  technologies.  Panomics has filed   
  more than 15 patents, 7 of which    
  are issued.  Panomics has now 12    
  full-time employees; 4 of them are  
  PhD/MD scientists, and it occupies  
  a facility with 6,500 square feet   
  of lab and office space in Redwood  
  City, California.   Panomics also   
  has a strong scientific consultant  
  team including Michael Rosenfeld,   
  who is the members of National      
  Academy of Sciences.                
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Paradigm Pharmaceuticals, LLC**\  Fatih Uckun\
  St. Paul, MN                        Tel: 612-965-4894\
                                      Email: fatih_uckun@ih.org

  Paradigm Pharmaceuticals, LLC is a  
  start-up, for-profit Minnesota      
  limited liability pharmaceuticals   
  company. The goal of Paradigm       
  Pharmaceuticals is to develop new   
  and active pharmaceuticals for the  
  prevention and treatment of viral   
  infections and malignancies.        
  Paradigm Pharmaceuticals is         
  currently developing                
  bench-to-bedside patent-applied     
  technologies towards final product  
  and approval stages in order to     
  produce the highest quality         
  pharmaceutical and consumer health  
  care products in the world.         
  Complete in house laboratory set-up 
  with state-of-the-art equipment is  
  established. Extensive research     
  studies have been conducted and the 
  most beneficial and extraordinary   
  drug candidates have been tested in 
  animal models to confirm efficacy,  
  potency, and toxicity.              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Perinatronics Medical Systems**\  Thomas Frank\
  Millersville, MD                    Tel: 410-987-1305\
                                      Email: thomasfrank@covad.net

  Perinatronics develops and          
  clinically tests innovative         
  diagnostic medical                  
  instrumentation.  In obstetrics, we 
  developed a unique, patented        
  non-invasive fetal heart rate       
  monitor used for advanced           
  antepartum testing and monitoring   
  during labor and delivery.  It is   
  the only device available to        
  non-invasively monitor clinically   
  significant fetal heart rate        
  beat-to-beat variability.           
  Recently, our priority has been the 
  development of our innovative       
  patent-pending ECG triggering       
  system to improve cardiac magnetic  
  resonance imaging.  This ECG gating 
  system provides for reliable and    
  robust triggering of the moving     
  heart and coronary arteries.  We    
  work closely with leading           
  physicians at the University of     
  Maryland School of Medicine, Johns  
  Hopkins Hospital, Barnes Hospital,  
  and the National Institutes of      
  Health Clinical Center.             
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Persyst Development               Scott Wilson\
  Corporation**\                      Tel: 858-755-4565\
  Del Mar, CA                         Email: scottw@eeg-persyst.com

  Persyst is the world's largest      
  developer of software for EEG       
  (electroencephalograph) review and  
  analysis. Current markets include   
  clinical review, epilepsy           
  monitoring and diagnosis, and ICU   
  monitoring. Our recently developed  
  AutoLearn™ technology allows        
  patient dependent algorithms to be  
  developed on the fly from EEG and   
  critical care parameters. The EEG   
  technician marks a single example   
  of the pattern of interest and the  
  neural networks are trained         
  instantaneously (\< 1 s) without    
  user intervention. New examples can 
  be identified to refine the         
  algorithm without retraining. The   
  same technology allows patient      
  independent algorithms to learn     
  over time.                          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Phantoms by Design Inc.**\        Thomas Burke\
  Bothell, Wa                         Tel: 425-481-3515\
                                      Email: tburke@pbdinc.net

  PBD produces anthropomorphic        
  phantoms of human hearts for use in 
  developing and testing percutaneous 
  interventional devices and          
  procedures such as AF ablation,     
  septal defect closure and valve     
  replacement.  The physical models   
  are based on clinical image data    
  and provide a stable, well          
  characterized, clinically relevant  
  environment which reproduces the    
  form and key functionality of       
  native heart tissues. Properly      
  employed, PBD's models will         
  streamline development cycles,      
  speeding the delivery of            
  interventions in less time with     
  enhanced performance. Though        
  phantoms will never replace animal  
  and human testing, they can reduce  
  the time and expense of animal      
  testing and improve clinical trial  
  outcomes.                           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Pharmacon International, Inc.**\  Renee Arnold\
  New York, NY                        Tel: 212-480-4500\
                                      Email: rarnold@pharmacon.com

  Pharmacon International, Inc. has   
  created a proprietary software      
  program, EB-Health ALERTS©, that    
  manages information to improve      
  health outcomes.  EBH ALERTS™       
  (Evidence-Based Health Automated    
  Live E-Health Response Tracking     
  System) is a fully automated,       
  remote, prospective health and      
  disease monitoring tool, accessible 
  via Internet and interactive voice  
  response, which will (1) facilitate 
  identification of people at         
  greatest risk of developing         
  specific diseases, (2) take steps   
  to intervene early to prevent       
  disease onset and (3) improve       
  management of patients with chronic 
  diseases. The program aims to       
  enhance patient-provider            
  communication through automation    
  and decrease healthcare costs by    
  providing cost-effective deployment 
  of disease management programs.     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **PharmaSeq, Inc.**\                Wlodek Mandecki\
  Monmouth Jct., NJ                   Tel: 732-355-0100\
                                      Email: mandecki@pharmaseq.com

  PharmaSeq\'s provides ultra         
  high-throughput, low-cost,          
  multiplex bioassays and instruments 
  for research and clinical use.  The 
  Company has pioneered a unique      
  technology based on an ultra-small  
  silicon integrated circuit, a       
  microtransponder, which, when       
  activated by laser light emits a    
  radio frequency signal carrying a   
  unique identification code.  In     
  biological applications,            
  microtransponders are read in a     
  flow-based instrument developed by  
  the Company.  The first             
  applications are in detecting       
  genetic abnormalities (mutations,   
  SNPs), such as the cystic fibrosis  
  assay.  The Company plans to move   
  forward with applications in other  
  aspects of genomics, proteomics,    
  pharmaceutical drug discovery, and  
  combinatorial chemistry.            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Physical Sciences Inc.**\         Mark Druy\
  Andover, MA                         Tel: 847-491-3272\
                                      Email: druy@psicorp.com

  Physical Sciences Inc., a 33 year   
  old company, develops and           
  commercializes advanced             
  technologies for the aerospace,     
  energy, environmental,              
  manufacturing, and medical          
  markets.  PSI is currently          
  developing an ultra-sensitive       
  system for direct measurement of    
  singlet oxygen during Photodynamic  
  therapy (PDT).  Photodynamic        
  therapy (PDT) is a rapidly          
  developing and extremely promising  
  branch of oncology. FDA approval    
  has been granted for treatment of   
  esophageal and certain lung cancers 
  using PDT. To date, there is no     
  commercially available instrument   
  that can directly measure the real  
  time profiles of singlet oxygen     
  during PDT treatment.  Singlet      
  oxygen formation is a key factor in 
  understanding the response of the   
  cancer to PDT.  An instrument that  
  can measure real-time profiles will 
  greatly accelerate the ability of   
  PDT to treat various cancers.       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **PhysioGenix, Inc.**\              John Seman\
  Wauwatosa, WI                       Tel: 414-431-6600\
                                      Email: john.seman@physiogenix.com

  PhysioGenix was formed by leading   
  researchers at the Medical College  
  of Wisconsin (MCW) to commercialize 
  the Founders' vision of reducing    
  drug failures in clinical trials by 
  improving pre-clinical animal       
  models for predictive toxicology,   
  drug screening, and target          
  validation. To fulfill this vision  
  the Company has brought physiology  
  to the genome by engineering        
  multigenic rat models using         
  genetics, genomics, and             
  bioinformatics to match human       
  disease. PhysioGenix uses these     
  animals to provide contract         
  research services related to        
  predictive toxicology and           
  therapeutic proof-of-concept to     
  pharmaceutical companies to help    
  them accelerate their product       
  development processes.              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Pinnacle Technology Inc.**\       Donna Johnson\
  Lawrence, KS                        Tel: 785-832-8866\
                                      Email: donnaj@pinnaclet.com

  Pinnacle develops and               
  commercializes innovative medical   
  devices for animal research. The    
  company targets the pharmaceutical  
  industry, research laboratories and 
  universities that use over 20       
  million mice and rats each year in  
  the United States.  Turnkey         
  Pinnacle systems include            
  biosensors, wireless or tethered    
  data acquisition systems, and       
  software.  Pinnacle's sensors and   
  systems are well suited for high    
  throughput drug screening, and they 
  enable research that will elevate   
  our understanding of the chemical   
  origins of behavior and many        
  disorders including: sleep          
  disorders, heart disease,           
  Parkinsons, and Alzheimers.         
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Platypus Technologies**\          Barbara Israel\
  Madison, WI                         Tel: 608-237-1274\
                                      Email: bisrael@platypustech.com

  Platypus Technologies is a          
  Bio/Nanotechnology company.  We are 
  developing a new generation of      
  diagnostics, monitors and sensors   
  based on the use of nanostructured  
  surfaces and liquid crystals.       
  Platypus technology enables label   
  free detection of proteins, cells,  
  viruses and volatiles.  Our         
  products will allow scientists to   
  monitor large scale outbreaks of    
  diseases such as avian influenza    
  using sensitive, rapid assays that  
  permit digital acquisition,         
  analysis and sharing of data and    
  that can be conducted in low        
  technology environments.  Platypus  
  technology will also permit the     
  quantitative, individual monitoring 
  of exposure to environmental        
  toxins, such as pesticides. Our     
  products will be useful in basic    
  research, clinical medicine,        
  environmental studies and military  
  applications. Platypus has received 
  over \$10 million in competitive    
  SBIR funds to advance the           
  development of this powerful        
  platform technology.                
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **PortaScience Inc.**\              Wai Law\
  Moorestown, NJ                      Tel: 847-491-3273\
                                      Email: wailaw@portascience.com

  PortaScience Inc. focuses on new    
  product development for             
  point-of-care diagnostic tests      
  which address clinical and consumer 
  markets.  The team has experience   
  in commercializing over 50 FDA      
  approved diagnostic products, and   
  has licensed out or commercialized  
  five products in the last five      
  years.                              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Praevium Research, Inc.**\        Vijaysekhar Jayaraman\
  Santa Barbara, CA                   Tel: 805-448-4008\
                                      Email: vijay@praevium.com

  Praevium Research, Inc. is a        
  developer of compact                
  semiconductor-based sources of      
  broadband optical radiation for     
  biomedical imaging and other sensor 
  applications. Current development   
  efforts include broadband sources   
  for Optical Coherence Tomography,   
  multi-wavelength laser arrays for   
  diffuse optical spectroscopy, and   
  dense laser clusters for near       
  infrared agricultural spectroscopy. 
  Praevium core technologies include  
  semiconductor wafer bonding,        
  processing, and epitaxial growth,   
  and micropackaging of semiconductor 
  sources. These technologies are     
  being employed to create sources    
  with maximum wavelength coverage in 
  conjunction with minimum size and   
  power dissipation.                  
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Premitec Inc.**\                  Helmut Eckhardt\
  Raleigh, NC                         Tel: 919-424-4456\
                                      Email: eckhardt@premitec.com

  Premitec, Inc. was founded as a     
  spin-off from the Biomedical        
  Microsensor Laboratory and the      
  Center for Advanced Manufacturing   
  Processes and Materials at North    
  Carolina State University in        
  Raleigh.  The company uses its      
  expertise in microfabrication       
  technology to provide research,     
  product development and             
  manufacturing expertise to medical  
  device, diagnostics, genomics and   
  drug screening companies.  In       
  addition the company is developing  
  proprietary biomedical sensors and  
  implant devices.\                   
  Premitec's platform technology      
  combines its microfabriation        
  technology for flex substrates with 
  the proprietary A-coatTM            
  encapsulation technology enabling   
  the development of flexible,        
  biocompatible implantable           
  microelectrode arrays and devices   
  used for neurostimulation, in-vivo  
  diagnostics as well as the          
  development of low-cost, disposable 
  microfluidics components and        
  sensors for in-vitro diagnostics.   
  Products under development in       
  collaboration with corporate and    
  academic partners and partially     
  funded by SBIR grants form the NIH  
  are microelectrode array devices    
  for neural stimulation, in-vivo     
  glucose sensors and novel           
  electrochemical immunosensors.      
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **ProteomTech, Inc.**\              David Hagebush\
  Emeryville, CA                      Tel: 510-597-9131\
                                      Email:
                                      hagebush@protoemtech-inc.com\
                                      dhagebush@yahoo.com

  Therapeutics Research and           
  Development:\                       
  Proteomtech, Inc. is a              
  product-driven pharmaceutical       
  research and development company.   
  PTI is based upon IP for protein    
  refolding (US patent 6,583,268),    
  Pt-Fold TM.\                        
  \                                   
  Our focus and core technology is    
  built around developing therapeutic 
  proteins optimally refolded from E. 
  coli inclusion bodies that are      
  difficult to recover via competing  
  technologies.\                      
  Using Pt-Fold, ProteomTech has      
  developed a pipeline of protein     
  drug candidates. Proteomtech holds  
  worldwide composition of matter,    
  method of manufacturing and methods 
  of treating cancer patents for a    
  protein therapeutic candidate for   
  oncology, and has submitted method  
  of manufacturing patents for        
  protein therapeutic candidates for  
  chronic obstructive pulmonary       
  disease and thrombolytic            
  indications.                        
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **ProThera Biologics**\             Yow-Pin Lim\
  East Providence, RI                 Tel: 401-301-2046\
                                      Email: Yow-Pin_Lim_MD@brown.edu

  ProThera Biologics develops         
  \"theranostic\" and therapeutic     
  products for serious human diseases 
  such as sepsis and cancer.          
  Theranostics represent a new market 
  area with enormous potential for    
  growth which utilize predictive     
  tests to make critical,             
  personalized treatment decisions.   
  The company is currently focusing   
  on novel uses of natural plasma     
  protease inhibitors (Inter-alpha    
  inhibitors) which are involved in   
  the pathological processes of       
  systemic inflammation and cancer    
  metastasis. Utilizing inter-alpha   
  inhibitors as integrated            
  theranostic and therapeutic         
  biomolecules, ProThera Biologics    
  will target sepsis and cancer, a    
  clinical arena representing         
  wide-spread patient populations     
  with a significant unmet medical    
  need.                               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **QED Labs**\                       Pam Thuman-Commike\
  San Jose, CA                        Tel: 408-295-8347\
                                      Email: pam@qedlabs.com

  QED Labs provides software for      
  solving complex computational       
  biology problems. We develop        
  computational research tools for    
  three-dimensional structural        
  determination from electron         
  microscopy data that enable         
  biologists, at all levels of        
  structure determination, to easily  
  process their data.  QED Labs       
  accomplishes this with innovative   
  software that guides user on how,   
  when, and why to perform data       
  processing operation.               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Sci-Tec, Inc.**\                  Val Golovlev\
  Knoxville, TN                       Tel: 865-671-2166\
                                      Email: golovlev@aol.com

  Sci-Tec, Inc. is a microarray       
  technology company offering         
  equipment, software, consumables    
  and reagents for life science       
  research and biomedical             
  applications.\                      
  Sci-Tec\'s core product is AuroGen  
  microarray system, which has a      
  unique capability to detect and     
  quantify DNA, RNA and proteins on   
  high-density microarrays without    
  chemical modification of target     
  molecules. The unique, yet          
  affordable microarray platform can  
  be used in various applications     
  offering advantage of personal      
  microarray system to researchers    
  and medical practitioners working   
  in the fast expending fields of     
  genetic analysis, medical           
  diagnosis, environmental analysis,  
  drug discovery, forensic analysis,  
  and biodefense.                     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **SibTech, Inc.**\                  Joseph Backer\
  Newington, CT                       Tel: 860-953-1164\
                                      Email: jbacker@sibtech.com

  SibTech, Inc. is developing         
  VEGF-based imaging constructs for   
  targeting and imaging angiogenesis. 
  The constructs for fluorescent and  
  nuclear medicine imaging, based on  
  proprietary single-chain VEGF, are  
  successful in animal models and     
  strategies for clinical development 
  are being explored. In developing   
  these constructs, SibTech utilized  
  its proprietary technology for      
  conversion of biopharmaceutical     
  proteins into the carriers of       
  therapeutic and diagnostic agents.  
  SibTech is offering this technology 
  for licensing and/or co-development 
  to the companies that wish to       
  expand applications and patent life 
  of their proprietary                
  biopharmaceutical proteins.         
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **SoloHill Engineering, Inc.**\     Timothy Solomon\
  Ann Arbor, MI                       Tel: 734-973-2956\
                                      Email: solohill@ic.net

  SoloHill develops and delivers      
  microcarrier technology for use in  
  the human and animal pharmaceutical 
  industries.  SoloHill has responded 
  to industry needs over the past     
  decade by developing animal protein 
  free microcarriers, protocols for a 
  variety of cell culture based       
  vaccines, and whole infected-cell   
  harvest technology.\                
  The Company's protocols are for     
  producing human influenza vaccine   
  via cell culture technology in      
  bioreactors using SoloHill's Hillex 
  ® microcarriers, Vero or MDCK cell  
  lines and, animal protein free      
  media.  SoloHill continues to seek  
  partnerships and/or licensing       
  arrangements with pharmaceutical    
  manufacturers that have an interest 
  in utilizing microcarrier based     
  cell culture technologies.          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Source Signal Imaging, Inc.**\    Richard Greenblatt\
  San Diego, CA                       Tel: 619-234-9935\
                                      Email: reg@sourcesignal.com

  Source Signal Imaging (SSI)         
  provides innovative, powerful, and  
  useable software to measure and     
  visualize human brain dynamics,     
  used by researchers and clinicians  
  worldwide.  SSI specializes in      
  advanced signal and image           
  processing, enabling investigators  
  to combine electroencephalography   
  (EEG), magnetoencephalography (MEG) 
  and magnetic resonance imaging      
  (MRI) to determine where events     
  happen in the brain, how events     
  change over time, and how brain     
  regions interact.  SSI's EMSE^®^    
  Suite software is used to study     
  cognition, perception, and memory.  
  Diseases such as autism,            
  schizophrenia, and epilepsy are     
  characterized by disordered brain   
  dynamics, and EMSE^®^ allows        
  clinicians to better diagnose and   
  understand these diseases.          
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **SpectraGenetics LLC**\            Cheryl Telmer\
  Pittsburgh, PA                      Tel: 412-488-9350\
                                      Email:
                                      cheryl.telmer@spectragenetics.com

  SpectraGenetics supplies the        
  biomedical research market with     
  innovative products for analyzing   
  genes and gene function. The        
  company's reporter-tagged           
  full-length mammalian genes are     
  sold to cell and molecular          
  biologists in academic, government  
  and industrial laboratories. These  
  products overcome many of the       
  drawbacks of currently available    
  reporter systems, leading to more   
  meaningful experimental data. The   
  company's Peptide Mass Signature    
  Genotyping (PMSG) products provide  
  sensitive, comprehensive and        
  accurate sequence information       
  particularly suited to clinical     
  cancer research where existing      
  sequencing methods fail. RT-PMSG    
  products for studies of gene        
  expression, including alternative   
  splicing, provide complete          
  characterization of variation using 
  a single kit.                       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **SpectRx Inc.**\                   Shabbir Bambot\
  Norcross, GA                        Tel: 847-491-3274\
                                      Email: sbambot@spectrx.com

  SpectRx, Inc. (OTCBB: SPRX) uses    
  innovative and minimally invasive   
  technologies in products and        
  product development activities for  
  the diagnosis and therapy of cancer 
  and diabetes. The company is        
  currently in FDA pivotal studies    
  with its non-invasive cervical      
  cancer detection product and is     
  commercializing this through its    
  subsidiary, Guided Therapeutics,    
  Inc. In the diabetes arena, the     
  company has innovative solutions    
  for insulin delivery and glucose    
  monitoring. SpectRx markets the     
  SimpleChoice® line of diabetes      
  management products, which include  
  insulin pump disposable supplies.   
  SpectRx is also developing a        
  consumer device for continuous      
  glucose monitoring.                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Synthasome**\                     Anthony Ratcliffe\
  San Diego, CA                       Tel: 858-490-9401\
                                      Email:
                                      anthonyratcliffe@synthasome.com

   Synthasome is a biotechnology      
  company developing regenerative     
  medicine products primarily for     
  musculoskeletal applications        
  (tendon, ligament and cartilage     
  repair), using tissue engineering   
  technologies supported by new       
  intellectual property.  The Company 
  uses federal research grants to     
  drive early product development,    
  and so far has received over \$3    
  million in grants. The first        
  product in our pipeline is a device 
  for assisting surgical repair of    
  injured rotator cuff tendons        
  (approx. \$100 million market), the 
  product is anticipated to enter the 
  market place in 2007, and will then 
  be followed by products for knee    
  articular cartilage repair.         
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **SynVax, Inc.**\                   Amrit Judd\
  North Logan, UT                     Tel: 435- 713-4917\
                                      Email: synvax@aol.com

  SynVax, Inc. is a biopharmaceutical 
  company with a mission to           
  successfully discover, develop, and 
  commercialize pharmaceutical        
  products for use in infection,      
  pain, and cardiology.  At least     
  five significant discoveries are    
  currently ready for development,    
  and more are in the pipeline.       
  Animal studies have been done on    
  three products.  The products are   
  based on advanced peptide           
  structure-function analyses and     
  expertise in peptide synthesis.     
  Patent has been issued on one       
  product and pending on another.     
  The pharmaceutical markets the      
  company will address are currently  
  in excess of \$10 billion in annual 
  sales.                              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **SynZyme Technologies, LLC**\      Carleton Hsia\
  Irvine, CA                          Tel: 949-453-1072\
                                      Email: synzyme@synzyme.com

  SynZyme Technologies, LLC, is a     
  privately-held, California-based,   
  Delaware biopharmaceutical company. 
  Utilizing its proprietary platform  
  technology of polynitroxylation,    
  SynZyme is engaged in the           
  development of a drug pipeline      
  based on targeted delivery of caged 
  nitric oxide free radical           
  therapeutics. These products belong 
  to a new class of stable,           
  metal-free radicals with targeted   
  antioxidant and enzyme-mimetic      
  activities, which are intended for  
  the treatment of                    
  ischemia/reperfusion and            
  inflammatory-related diseases       
  associated with inadequate blood    
  flow.                               
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Talaria Inc**\                    Peter Dunbar\
  Seattle, WA                         Tel: 206-748-0443\
                                      Email: pjdunbar@comcast.net

  Talaria Inc has a proprietary       
  "builder" that enables development  
  of healthcare eLearning programs    
  over the internet. This enables our 
  content developers to originate,    
  modify and publish sophisticated    
  eLearning programs from home or     
  internet café anywhere in the world 
  yet have the functionality of a     
  desktop or server application.\     
  This technology drastically reduces 
  our cost of development by reducing 
  travel costs and improving workflow 
  while also improving quality of     
  content, by enabling content        
  experts from anywhere in the world  
  to contribute without ever leaving  
  home. Customers delighted by        
  Talaria products include the US     
  Army, VA, major Pharmaceutical      
  companies and hospitals.            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Talisman Limited**\               Paul Cumming\
  Vienna, VA                          Tel: 703-938-0300\
                                      Email: pc@talmed.com

  The Quality Donor System (tm)(QDS), 
  an FDA 510(k) cleared Medical       
  Device, is Talisman\'s principal    
  achievement. It may be the world\'s 
  only scientifically and medical     
  production line proven automated    
  multimedia blood donor health       
  history interviewing system. Since  
  2001 QDS has completed more than    
  450,000 interviews at five          
  different blood and medical         
  organizations and is currently      
  operating at the rate of 350,000    
  interviews/year. It runs on tablet  
  computers in standalone or          
  network/Web modes. It has been      
  shown repeatedly to vastly increase 
  donor and staff satisfaction,       
  reduce FDA errors by over 60% and   
  staff time by over 80% and to       
  increase donor honesty.             
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Talking Lights LLC**\             Elmer Lupton\
  Boston, MA                          Tel: 847-491-3275\
                                      Email: neil@talking-lights.com

  Talking Lights LLC uses existing    
  lighting in a facility to create    
  inexpensive unique communication    
  networks and precise locator        
  capability.   Lights become locator 
  beacons while still providing       
  non-flickering, strong              
  illumination.   Applications        
  include assistance for persons with 
  cognitive disorders like            
  Alzheimer\'s patients and           
  traumatic brain injury patients,    
  wayfinding and guidance in retail   
  facilities,  office buildings,      
  schools, hospitals and care         
  facilities,  and specialized        
  assistive areas like guidance for   
  the blind.   A capability like GPS  
  indoors is created.                 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Targeted Gene Delivery, Inc.**\   Steven Hefeneider\
  Portland, OR                        Tel: 503-525-4878\
                                      Email: hefeneid@ohsu.edu

  Targeted Gene Delivery, Inc.,       
  develops immune regulatory          
  therapeutics derived from bacterial 
  and viral proteins.  Bacteria and   
  viruses have the ability to encode  
  proteins designed to regulate the   
  host immune system.  These proteins 
  can be identified and modified to   
  form unique therapeutics able to    
  either enhance or diminish the      
  immune system.  Therapeutics        
  derived from these proteins have    
  the potential to alter the course   
  of disease.  Specific applications  
  include anti-inflammatories for use 
  in chronic diseases such as septic  
  shock and meningitis, and immune    
  stimulatory products for use in     
  immune compromised individuals.     
  Targeted Gene Delivery has          
  developed a proprietary             
  anti-inflammatory peptide with      
  potential application in the        
  treatment of several chronic        
  inflammatory diseases.  The company 
  is focused on the commercialization 
  of this novel therapeutic, and      
  development of additional immune    
  regulatory peptides.                
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **TechEn, Inc.**\                   Arthur DiMartino\
  Milford, MA                         Tel: 508-478-0042\
                                      Email: AAD@techen.com

  TechEn designs, develops and        
  markets non-invasive optical brain  
  imaging solutions. The innovative,  
  portable devices are sold           
  world-wide and provide fast         
  quantitative assessment, reducing   
  the cost for treatment and          
  improving rehabilitation. Working   
  in conjunction with Harvard's       
  teaching hospital, MGH, TechEn has  
  developed propriety real-time       
  algorithms, hardware, software and  
  disposables.  Current applications  
  include: stroke rehabilitation,     
  traumatic brain injury, autism,     
  epilepsy and early child            
  development.\                       
  With twenty-two years experience in 
  all stages of innovation, TechEn    
  offers clients a full array of      
  electronic product design solutions 
  and production services. Recent     
  programs include Bone Densitometry, 
  ICU Glucose Monitor, GPS Signal     
  Simulator and Wireless Biotech      
  Sensing.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **The Virtual Reality Medical       Mark Wiederhold\
  Center**\                           Tel: 858-642-0267\
  San Diego, CA                       Email: mwiederhold@vrphobia.com

  The Virtual Reality Medical Center  
  (VRMC) delivers innovative pain     
  distraction products using virtual  
  reality technology integrated with  
  medical science. The patient wears  
  a small, comfortable device with    
  earphones and a 3-D visual display  
  that immerses them in an            
  interactive world. Such immersion   
  relieves pain by reducing attention 
  to it. VRMC-developed worlds        
  include Enchanted Forest, Dream     
  Castle, and others. These pain      
  distraction products are important  
  adjuncts to other pain management   
  methods, such as pharmaceuticals,   
  because the patient is more in      
  control of managing his or her pain 
  relief, thus reducing medication    
  and visits to health professionals. 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Therapyx, Inc.**\                 Thomas Conway\
  Buffalo, NY                         Tel: 716-829-2528\
                                      Email: thomasc@therapyx.org

  Therapyx, Inc. is a privately held  
  biopharmaceutical company that      
  focuses on the development and      
  commercialization of nanoadjuvants  
  for innovative therapeutic and      
  vaccination strategies.  The        
  company's nanoadjuvant platform     
  represents a general strategy for   
  the immunotherapy of disease        
  through the application of          
  slow-release\                       
  adjuvants.  While the company's     
  first product is targeted for major 
  cancers, including lung cancer      
  (first indication), breast cancer,  
  melanoma and other solid tumors,    
  Therapyx, Inc. has a broad pipeline 
  of products at the pre-clinical     
  stage for applications in           
  autoimmune\                         
  and infectious disease.             
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Therataxis, LLC**\                Raghu Raghavan\
  Baltimore, MD                       Tel: 410-464-1418\
                                      Email: raghu@therataxis.com

  Therataxis models brain transport   
  processes and designs delivery      
  methods for therapies.  The         
  simulation and prediction of        
  transport mechanisms, and our       
  proprietary direct delivery         
  devices, provide the necessary link 
  in developing   successful          
  therapies of the brain by ensuring  
  proper delivery.  Our currently     
  marketed products are surgical      
  simulation software and             
  simulation-based device designs.    
  We offer services in medical image  
  analysis, biomedical simulations,   
  therapy planning, and management of 
  appropriate research.  In addition  
  to our industrial customers, the    
  company has academic partnerships   
  with major universities through     
  grants and contracts.\              
  Our focus is to improve delivery of 
  therapeutics directly into brain    
  and other solid tissue (prostate,   
  tumor, etc.) by predicting the      
  distribution of the therapy -       
  either particulate or energy - for  
  a specific individual and disease   
  state.                              
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Thromgen, Inc.**\                 Alvin Schmaier\
  Cleveland, OH                       Tel: 216-368-1172\
                                      Email: alvin.schmaier@case.edu

  Thromgen Inc., founded in 1995, is  
  a privately owned early-stage       
  biotechnology company that is       
  discovering and developing novel    
  treatments for diseases related to  
  a new class of thrombin receptor    
  inhibitors (also called antagonists 
  or blockers).  The novel mechanisms 
  of the technology allows Thromgen's 
  therapeutic scope to include        
  cardiovascular-, oncologic-, and    
  inflammatory-related diseases.      
  Initially, the Company is focusing  
  on acute coronary syndromes and     
  prostate cancer with its lead       
  candidate, ThrombostatinTM.  The    
  Company is a spin-out from the      
  University of Michigan (Ann Arbor)  
  located in Ann Arbor, Michigan.     
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Tissue Technologies LLC**\        Irwin Cohen\
  Richmond, VA                        Tel: 804-301-7839\
                                      Email: kelmanc@comcast.net

  Tissue Technologies LLC is a        
  \"start up\" dedicated to healing   
  and prevention of wounds. Our first 
  product, a protease sequestering    
  dressing for chronic wounds is      
  inexpensive and effective. We are   
  developing other materials for the  
  same purpose which will be more     
  potent and user friendly. Simiar    
  products to treat gingivitis and    
  ostony wound sites are planned.     
  Also under development is a         
  bed-side color indicator for wound  
  protease activity which will help   
  the caregiver decide on therapy. In 
  addition, we have submitted a       
  patent on a device to prevent       
  pressure ulcers.  The protease      
  sequestration technology will apply 
  also to products to prevent skin    
  aging.  Finally, TT wound prodcuts  
  will be for animals as well as man. 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **TissueTech, Inc. & Bio-Tissue,    Amy Tseng\
  Inc.**\                             Tel: 305-412-4430\
  Miami, FL                           Email: info@biotissue.com

  TissueTech uses its proprietary     
  cyro-preservation technologies to   
  produce amniotic membrane tissue    
  products with miraculous properties 
  in promoting anti-inflammatory,     
  anti-scarring and anti-angiogenic   
  actions. The Company's two          
  commercialized products (AmniGraft® 
  and ProKera™) are targeted to       
  restore eye surface damages caused  
  by corneal or conjunctival ulcers,  
  chemical burns, and pterygium, etc. 
  With increasing number of           
  publications since 1995, the        
  concept of ocular surface           
  reconstruction using these products 
  has gained popularity among         
  ophthalmic community. This is       
  proven by the exceptional growth    
  the Company experienced last year.  
  The Company also has a pipeline     
  includes several stem-cell          
  therapies and novel medical devices 
  at different stages of development. 
  The Company's goal is to expand the 
  therapeutic actions of its          
  tissue-engineered products to other 
  body sites in the future.           
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **TRS Technologies, Inc.**\         Paul Rehrig\
  State College, PA                   Tel: 814-238-7485\
                                      Email: paul@trstechnologies.com

  TRS is a producer of specialty      
  piezoelectric products for navy     
  sonar, medical ultrasound,          
  precision sensor, and precision     
  positioning markets.  TRS has been  
  an innovator in the area of         
  piezoelectric materials             
  technologies with developments such 
  as new materials for high power     
  sonar projectors; machinable        
  ceramics for the production of      
  ultrasound arrays; high strength    
  ceramics for high force actuators;  
  and single crystal piezoelectrics   
  for broad band ultrasound           
  transducers, high sensitivity       
  vibration sensors, and high         
  displacement actuators.  TRS        
  currently has \$4 million in annual 
  sales and has received over \$1     
  million in investment capital for   
  commercialization of new materials  
  technologies.                       
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **VeriFax Corporation**\            Ruth Shrairman\
  Boulder, CO                         Tel: 303-581-9770\
                                      Email: shrairmr@yahoo.com

  VeriFax is a Chapter S Colorado     
  Corporation. It is a small R&D      
  enterprise with the main mission to 
  develop high quality, cost          
  effective security and biomedical   
  devices based on IP developed by    
  the company founders. The           
  biomedical device "NeuroskillTM" is 
  intended to assess fine motor       
  control fluctuations in people with 
  neurological disorders, such as     
  Parkinson's disease and stroke,     
  while "ImpairscopeTM" is a device   
  to assess impairment due to         
  environmental intoxication and      
  result of substance abuse. The      
  measures of impairment provided by  
  Neuroskill and Impairscope can be   
  considered as potential clinical    
  markers for prospective             
  applications. The biometric device  
  "AutographTM" offers an easy,       
  cost-effective and universally      
  accepted solution for signature     
  verification with unprecedented     
  accuracy. It can be used in both    
  cyber security and physical         
  security\                           
  systems.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Vesticon, Inc.**\                 Cathryn Epley\
  Portland, OR                        Tel: 503-230-0539\
                                      Email: cepley@vesticon.com

  Vesticon is focused on the          
  development of a suite of           
  interelated solutions to make it    
  easier and more lucrative for       
  physicians to deal with one of the  
  most frustrating areas in medicine: 
  the diagnosis and management of the 
  dizzy patient.  Building on the     
  assets of medical expertise that is 
  among the most extensive for this   
  field, Vesticon has funded          
  operations through NIH SBIR grants, 
  which now provide a baseline to     
  launch commercial activities to     
  dominate the vestibular device      
  market.  Direct costs related to    
  injuries from elderly fallers with  
  preventable vestibular problems     
  exceed \$10 billion; and Vesticon's 
  products will penetrate a           
  significant portion of this sector. 
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **Vical Incorporated**\             Marilyn Ferrari\
  San Diego, CA                       Tel: 858-646-1135\
                                      Email: mferrari@vical.com

  Vical\'s goal is to be an           
  integrated biopharmaceutical        
  company committed to the            
  development and commercialization   
  of vaccines and immunotherapies     
  based on its unique non-viral DNA   
  technology. Together with its       
  licensees and collaborators, Vical  
  is currently developing a number of 
  vaccine and therapeutic protein     
  product candidates for the          
  prevention or treatment of          
  infectious diseases, cancer, and    
  cardiovascular diseases.            
  Independent development programs    
  include vaccines for CMV and        
  anthrax, as well as novel           
  immunotherapeutics for treatment of 
  melanoma. Through collaborations    
  with others, Vical leverages its    
  technologies for applications that  
  may not be appropriate for          
  independent product development     
  efforts. Collaborators include      
  Merck, Sanofi, Merial (Merck/Sanofi 
  animal health joint venture), Aqua  
  Health (Novartis), AnGes MG,        
  Corautus Genetics, and the NIH. In  
  addition, Vical pursues contract    
  manufacturing opportunities to      
  leverage its infrastructure and     
  expertise in plasmid manufacturing, 
  and to provide revenues that        
  contribute to its independent       
  research and development efforts.   
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **VivaScan Corporation**\           Robert  A. Peura\
  West Boylston, MA                   Tel: 847-491-3278\
                                      Email: rpeura@aol.com

  VivaScan Corporation has developed  
  a painless testing device for blood 
  glucose monitoring by means of      
  unique noninvasive infrared         
  technology.  Currently diabetic     
  individuals stab themselves up to   
  ten times per day to determine      
  their blood glucose, or inject      
  insulin blindly at considerable     
  risk of complications. VivaScan's   
  monitor, designed by a team of      
  technical and clinical experts,     
  responds to the noninvasive test    
  needs of diabetic persons. A        
  proprietary platform technology has 
  evolved resulting in a personal     
  hand held monitor. With the         
  patented VivaScan glucose tester, a 
  simple and gentle squeeze of the    
  ear or finger is all it takes to    
  get an accurate reading of blood    
  glucose.                            
  ----------------------------------- -----------------------------------

  ----------------------------------- -----------------------------------
  **X-Ray Imaging Innovations**\      Gary Barnes\
  Birmingham, AL                      Tel: 205-492-7555\
                                      Email: gtbarnes@xrii.com

  X-Ray Imaging Innovations is a      
  company with expertise in medical   
  x-ray imaging technology. The       
  company\'s current efforts are      
  focused on the development of a     
  novel bedside (portable)            
  radiographic unit and in improving  
  general radiography and digital     
  tomosynthesis.  It is anticipated   
  that the new portable x-ray unit    
  will be easy to use and will result 
  in markedly improved images, images 
  comparable in quality to those      
  currently obtained with fixed       
  general radiographic units.  It is  
  also anticipated that the           
  improvements we are working on in   
  general radiography and digital     
  tomosynthesis will improve image    
  quality in a dose efficient manner. 
  ----------------------------------- -----------------------------------